Public Health England

Data tables of the Unlinked Anonymous Monitoring Survey of HIV and Hepatitis in People Who Inject Drugs

Surveillance Update: July 2016

Survey conducted by:	**National Infections Service, Public Health England**
Survey is supported by:	Public Health Wales and Public Health Agency Northern Ireland
Further Information:	Information on the Unlinked Anonymous Monitoring Surveys can be found at: https://www.gov.uk/government/statistics/people-who-inject-drugs-

About these data tables

These tables present data from the Unlinked Anonymous Monitoring Survey of People Who Inject Drugs (PWID) in contact with specialist services. This annual cross-sectional survey is co-ordinated by Public Health England, with support from Public Health Wales and Public Health Agency Northern Ireland. It is targeted at those who inject psychoactive drugs. These data tables are updated annually and made available on the Public Health England website. Data from the biennual sub-survey of people who inject image and performance enhancing drugs can be found in a separate set of tables published on the same web-page. A commentary on the surveillance tables is published in the Health Protection Report (HPR) which is also available on the Public Health England web pages.

Data are presented for the whole of England, Wales and Northern Ireland, and sub-divided by country and English region. Two regional breakdowns of England have been used in this dataset: the Public Health England Regions and the standard statistical regions (as defined in nomenclature of territorial units for statistics [NUTS]). In some of these areas, data from several years have been combined when less than 100 samples have been collected in a year. Regional level data should be interpreted *cautiously* as the survey recruits participants through a nationally reflective sample of the services provided to people who inject drugs. For clarity, percentages are given to two significant figures, and confidence intervals are not presented.

This set of data tables presents data for the period 2005 to 2015. Data from the survey for earlier years (the survey has been running since 1990) can be found in past sets of data tables which are available via the Public Health England website.

Suggested citation

For citation purposes the following is suggested: Public Health England, National Infection Service. Unlinked Anonymous Monitoring Survey of People Who Inject Drugs: data tables. July 2016. London, Public Health England.

Summary of survey methodology

This voluntary unlinked anonymous survey recruits people who inject drugs through specialist agencies throughout England, Wales and Northern Ireland. These agencies provide a range of services to those who inject illicit drugs, from medical treatment to needle and syringe programmes and outreach work. People using these services that are either currently injecting drugs or who have done so previously are asked to take part in the survey by service staff. Those who agree to take part provide a biological specimen that is tested anonymously for HIV, hepatitis C and hepatitis B. Behavioural and limited demographic information is collected through a brief anonymous subject-completed questionnaire linked to the specimen but unlinked from any client identifying information. This includes questions on the uptake of diagnostic (voluntary confidential) testing for HIV and hepatitis C, hepatitis B vaccination and the sharing of injecting equipment; participants may opt out of answering all questions. The questions asked have varied over time, and are focused on the use of psychoactive drugs.

The biological sample collected in the survey was changed from an oral fluid to a dried blood spot (DBS) during 2009 and 2010. From 2011 onwards, only DBS samples have been collected. The sensitivities of the tests on a DBS sample for antibodies to HIV, hepatitis C and hepatitis B core antigen, and that on an oral fluid sample for antibodies to HIV, are all close to 100%. However, the sensitivity of the oral fluid sample test for antibodies to hepatitis C is about 92% and that for antibodies to the hepatitis B core antigen is about 75%.

Number of sites recruiting participants each year: 2005-2015

Area											
	2005	**2006**	**2007**	**2008**	**2009**	**2010**	**2011**	**2012**	**2013**	**2014**	**2015**
London	15	13	10	11	12	9	10	14	13	14	12
Elsewhere in England and Wales	44	46	47	52	46	49	47	48	50	48	46
Northern Ireland	4	4	3	3	2	4	4	4	4	4	4
Total	**63**	**63**	**60**	**66**	**60**	**62**	**61**	**66**	**67**	**66**	**62**

Content

Abbreviations and footnotes used in this set of data tables

List of abbreviations used in this data set:

Anti-HIV	=	antibodies to HIV
Anti-HBc	=	antibodies to hepatitis B core antigen, a marker of current or past hepatitis B infection
Anti-HCV	=	antibodies to hepatitis C virus
HCV	=	hepatitis C virus
VCT	=	voluntary confidential test
DBS	=	dried blood spot
NUTS	=	nomenclature of territorial units for statistics

List of footnotes used in this data set:

˜ Age and gender not provided by all participants.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

§ The sensitivity of the oral fluid test for anti-HBc is approximately 75%.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

¶ The sensitivity of the oral fluid test for antibodies to hepatitis C (anti-HCV) is approximately 92%.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

‡ Sharing of needles and syringes among those who had last injected during the four weeks preceding participation in the survey.

‡‡ Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

⬩Prescribed a detox or maintenance drug regime.

⬩⬩Self-reports of ever receiving money, goods or drugs in exchange for sex.

⬩⬩⬩ Regional breakdowns not provided due to small numbers.

Table 1: HIV prevalence in people who inject drugs by gender and age; England, Wales and Northern Ireland: 2005-2015

Year			2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
All		**Anti-HIV Prevalence †**	**1.6%**	**1.3%**	**1.1%**	**1.6%**	**1.5%**	**1.1%**	**1.2%**	**1.3%**	**1.1%**	**1.0%**	**1.0%**
		Number of samples anti-HIV positive	52	42	41	51	49	35	35	43	34	31	26
		Total number of samples collected	3,176	3,240	3,580	3,209	3,289	3,288	2,838	3,389	3,144	3,091	2,721
Gender ~	**Male**	**Anti-HIV Prevalence †**	**1.7%**	**1.4%**	**1.2%**	**1.7%**	**1.5%**	**1.1%**	**1.4%**	**1.3%**	**1.2%**	**1.2%**	**1.0%**
		Number of samples anti-HIV positive	39	32	32	40	35	27	29	32	28	28	20
		Total number of samples collected	2,302	2,332	2,603	2,344	2,378	2,433	2,102	2,485	2,291	2,241	1,978
	Female	**Anti-HIV Prevalence †**	**1.4%**	**1.0%**	**0.88%**	**1.3%**	**1.4%**	**0.76%**	**0.88%**	**1.2%**	**0.73%**	**0.36%**	**0.84%**
		Number of samples anti-HIV positive	12	9	8	11	12	6	6	10	6	3	6
		Total number of samples collected	835	870	908	826	851	790	683	851	817	826	718
Age ~	**Under 25**	**Anti-HIV Prevalence †**	**1.1%**	**0.44%**	**0.59%**	**1.0%**	**0.25%**	**0.59%**	**0.84%**	**0.70%**	**0.54%**	**0.57%**	**1.7%**
		Number of samples anti-HIV positive	5	2	3	4	1	2	2	2	1	1	2
		Total number of samples collected	475	455	509	409	400	341	239	287	185	175	116
	25 to 34	**Anti-HIV Prevalence †**	**1.5%**	**1.3%**	**0.77%**	**1.5%**	**1.1%**	**0.58%**	**1.1%**	**0.84%**	**0.72%**	**0.41%**	**0.9%**
		Number of samples anti-HIV positive	21	18	12	19	14	7	11	10	8	4	7
		Total number of samples collected	1,393	1,412	1,567	1,296	1,246	1,214	1,027	1,186	1,107	964	782
	35 and over	**Anti-HIV Prevalence †**	**2.0%**	**1.6%**	**1.7%**	**2.0%**	**2.1%**	**1.5%**	**1.4%**	**1.6%**	**1.3%**	**1.3%**	**1.0%**
		Number of samples anti-HIV positive	25	20	23	27	31	24	20	29	23	24	17
		Total number of samples collected	1,228	1,278	1,373	1,361	1,474	1,598	1,465	1,781	1,801	1,898	1,780

~ Age and gender not provided by all participants.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

Table 2: Hepatitis B prevalence in people who inject drugs by gender and age; England, Wales and Northern Ireland: 2005-2015

Notes:
Anti-HBc is a marker for current or past hepatitis B infection. In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HBc tests on these two sample types are different[§].

Year			2005	2006	2007	2008	2009		2010		2011	2012	2013	2014	2015
Sample type			*Oral fluid*[§]	*Oral fluid*[§]	*Oral fluid*[§]	*Oral fluid*[§]	*Oral fluid*[§]	*DBS*	*Oral fluid*[§]	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*
All		**Anti-HBc Prevalence** [††]	**26%**	**28%**	**20%**	**18%**	**17%**		**16%**		**16%**	**17%**	**16%**	**14%**	**13%**
		Proportion anti-HBc positive	19%	21%	15%	13%	13%	11%	14%	15%	16%	17%	16%	14%	13%
		Number of samples anti-HBc positive	613	677	546	425	371	59	150	338	442	561	518	445	357
		Total number of samples collected	3,175	3,240	3,580	3,207	2,753	536	1,077	2,211	2,838	3,389	3,144	3,091	2,721
Gender [~]	**Male**	**Anti-HBc Prevalence** [††]	**26%**	**28%**	**20%**	**18%**	**17%**		**17%**		**16%**	**18%**	**17%**	**15%**	**14%**
		Proportion anti-HBc positive	20%	21%	15%	14%	14%	10%	13%	16%	16%	18%	17%	15%	14%
		Number of samples anti-HBc positive	457	486	389	322	280	40	110	265	344	441	382	344	272
		Total number of samples collected	2,302	2,332	2,603	2,342	1,982	396	817	1,616	2,102	2,485	2,291	2,241	1,978
	Female	**Anti-HBc Prevalence** [††]	**24%**	**27%**	**21%**	**16%**	**15%**		**15%**		**14%**	**13%**	**16%**	**12%**	**11%**
		Proportion anti-HBc positive	18%	20%	16%	12%	12%	14%	16%	12%	14%	13%	16%	12%	11%
		Number of samples anti-HBc positive	147	177	146	99	84	19	38	65	93	108	130	100	82
		Total number of samples collected	834	870	908	826	714	137	233	557	683	851	817	826	718
Age [~]	**Under 25**	**Anti-HBc Prevalence** [††]	**7.9%**	**11%**	**7.9%**	**4.2%**	**4.3%**		**8.3%**		**5.4%**	**4.9%**	**4.3%**	**2.3%**	**1.7%**
		Proportion anti-HBc positive	5.9%	8.4%	5.9%	3.2%	4.0%	1.0%	7.5%	7.2%	5.4%	4.9%	4.3%	2.3%	1.7%
		Number of samples anti-HBc positive	28	38	30	13	12	1	10	15	13	14	8	4	2
		Total number of samples collected	474	455	509	409	299	101	134	207	239	287	185	175	116
	25 to 34	**Anti-HBc Prevalence** [††]	**16%**	**20%**	**14%**	**11%**	**10%**		**8.5%**		**9.0%**	**9.3%**	**10%**	**5.7%**	**4.5%**
		Proportion anti-HBc positive	12%	15%	10%	7.9%	8.0%	7.1%	5.9%	8.7%	9.0%	9.3%	10%	6%	4%
		Number of samples anti-HBc positive	165	208	160	103	82	16	23	72	92	110	113	55	35
		Total number of samples collected	1,393	1,412	1,567	1,296	1,020	226	387	827	1,027	1,186	1,107	964	782
	35 and over	**Anti-HBc Prevalence** [††]	**43%**	**42%**	**32%**	**28%**	**26%**		**24%**		**22%**	**23%**	**22%**	**20%**	**17%**
		Proportion anti-HBc positive	33%	32%	24%	21%	20%	20%	22%	22%	22%	23%	22%	20%	17%
		Number of samples anti-HBc positive	400	405	329	282	253	39	111	242	328	410	390	377	310
		Total number of samples collected	1,228	1,278	1,373	1,359	1,282	192	495	1,103	1,465	1,781	1,801	1,898	1,780

[§] The sensitivity of the oral fluid test for anti-HBc is approximately 75%.

[~] Age and gender not provided by all participants.

[††] Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

Table 3: Hepatitis C prevalence in people who inject drugs by gender and age; England, Wales and Northern Ireland: 2005-2015

Notes:
In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV tests on these two sample types are different[¶].

Year			2005	2006	2007	2008	2009		2010		2011	2012	2013	2014	2015
Sample type			*Oral fluid* [¶]	*Oral fluid* [¶]	*Oral fluid* [¶]	*Oral fluid* [¶]	*Oral fluid* [¶]	*DBS*	*Oral fluid* [¶]	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*
All		**Anti-HCV Prevalence** [†††]	**45%**	**44%**	**43%**	**43%**	**47%**		**47%**		**43%**	**47%**	**49%**	**49%**	**50%**
		Proportion anti-HCV positive	42%	41%	39%	40%	43%	47%	41%	48%	43%	47%	49%	49%	50%
		Number of samples anti-HCV positive	1,325	1,316	1,412	1,274	1,183	252	442	1,051	1,234	1,601	1,543	1,517	1,371
		Total number of samples collected	3,175	3,240	3,580	3,209	2,753	536	1,077	2,211	2,838	3,389	3,144	3,091	2,721
Gender [~]	**Male**	**Anti-HCV Prevalence** [†††]	**47%**	**45%**	**43%**	**43%**	**47%**		**48%**		**45%**	**48%**	**48%**	**50%**	**50%**
		Proportion of samples anti-HCV positive	43%	41%	40%	40%	43%	45%	41%	49%	45%	48%	48%	50%	50%
		Number of samples anti-HCV positive	993	959	1,036	938	859	180	337	797	941	1,199	1,109	1,115	996
		Total number of samples collected	2,302	2,332	2,603	2,344	1,982	396	817	1,616	2,102	2,485	2,291	2,241	1,978
	Female	**Anti-HCV Prevalence** [†††]	**41%**	**42%**	**41%**	**41%**	**47%**		**42%**		**40%**	**45%**	**51%**	**47%**	**51%**
		Proportion of samples anti-HCV positive	38%	39%	37%	38%	42%	52%	40%	41%	40%	45%	51%	47%	51%
		Number of samples anti-HCV positive	315	336	340	313	301	71	93	231	275	383	415	388	364
		Total number of samples collected	834	870	908	826	714	137	233	557	683	851	817	826	718
Age [~]	**Under 25**	**Anti-HCV Prevalence** [†††]	**22%**	**25%**	**21%**	**22%**	**26%**		**27%**		**22%**	**24%**	**28%**	**25%**	**28%**
		Proportion of samples anti-HCV positive	20%	23%	20%	20%	21%	37%	25%	26%	22%	24%	28%	25%	28%
		Number of samples anti-HCV positive	97	106	100	83	62	37	34	54	52	68	52	43	32
		Total number of samples collected	475	455	509	409	299	101	134	207	239	287	185	175	116
	25 to 34	**Anti-HCV Prevalence** [†††]	**38%**	**36%**	**35%**	**36%**	**38%**		**36%**		**36%**	**38%**	**42%**	**40%**	**40%**
		Proportion of samples anti-HCV positive	35%	33%	32%	33%	35%	41%	31%	37%	36%	38%	42%	40%	40%
		Number of samples anti-HCV positive	483	472	507	426	355	92	119	309	366	446	467	385	316
		Total number of samples collected	1,393	1,412	1,567	1,296	1,020	226	387	827	1,027	1,186	1,107	964	782
	35 and over	**Anti-HCV Prevalence** [†††]	**62%**	**59%**	**59%**	**56%**	**59%**		**58%**		**53%**	**57%**	**55%**	**56%**	**56%**
		Proportion anti-HCV positive	57%	55%	54%	51%	54%	59%	54%	58%	53%	57%	55%	56%	56%
		Number of samples anti-HCV positive	704	697	744	699	691	113	265	642	773	1,015	998	1,060	1,001
		Total number of samples collected	1,227	1,278	1,373	1,361	1,282	192	495	1,103	1,465	1,781	1,801	1,898	1,780

[¶] The sensitivity of the oral fluid test for antibodies to hepatitis C (anti-HCV) is approximately 92%.

[~] Age and gender not provided by all participants.

[†††] Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

Table 4: Level of direct sharing among current injectors‡ by gender and age; England, Wales and Northern Ireland: 2005-2015

Year			2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
All		**Level of direct sharing ‡**	**28%**	**23%**	**23%**	**19%**	**19%**	**21%**	**17%**	**14%**	**16%**	**17%**	**16%**
		Number reporting direct sharing	504	445	487	343	339	363	224	236	265	259	227
		Total number answering question	1,812	1,910	2,093	1,798	1,814	1,701	1,305	1,660	1,622	1,540	1,406
Gender ~	**Male**	**Level of direct sharing ‡**	**25%**	**22%**	**22%**	**18%**	**17%**	**20%**	**16%**	**13%**	**15%**	**15%**	**14%**
		Number reporting direct sharing	348	315	351	235	234	254	160	167	188	181	146
		Total number answering question	1,381	1,432	1,586	1,328	1,382	1,299	1,020	1,261	1,219	1,169	1,056
	Female	**Level of direct sharing ‡**	**36%**	**27%**	**27%**	**23%**	**24%**	**27%**	**22%**	**17%**	**19%**	**21%**	**23%**
		Number reporting direct sharing	152	126	130	105	102	101	62	67	75	78	79
		Total number answering question	422	465	486	452	418	380	280	393	397	370	346
Age ~	**Under 25**	**Level of direct sharing ‡**	**38%**	**29%**	**26%**	**22%**	**27%**	**30%**	**24%**	**23%**	**31%**	**20%**	**25%**
		Number reporting direct sharing	119	100	100	60	71	64	33	41	38	24	16
		Total number answering question	314	345	384	272	264	215	137	181	121	118	65
	25 to 34	**Level of direct sharing ‡**	**28%**	**23%**	**25%**	**20%**	**20%**	**22%**	**17%**	**14%**	**17%**	**18%**	**21%**
		Number reporting direct sharing	235	202	247	159	147	150	89	93	111	100	99
		Total number answering question	831	863	984	802	751	691	523	643	646	557	466
	35 and over	**Level of direct sharing ‡**	**22%**	**19%**	**18%**	**17%**	**14%**	**18%**	**16%**	**12%**	**13%**	**15%**	**13%**
		Number reporting direct sharing	137	126	125	110	105	136	96	92	111	130	111
		Total number answering question	636	657	680	662	731	742	613	795	841	849	867

~ Age and gender not provided by all participants.

‡ Sharing of needles and syringes among those who had last injected during the four weeks preceding participation in the survey.

Table 5: Level of direct & indirect sharing among current injectors‡‡ by gender and age; England, Wales and Northern Ireland: 2005-2015

Year			2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
All		**Level of sharing (direct & indirect) ‡‡**	**50%**	**46%**	**45%**	**40%**	**36%**	**39%**	**35%**	**34%**	**39%**	**38%**	**38%**
		Number reporting sharing	908	888	964	700	656	663	460	566	641	597	542
		Total number answering question	1,809	1,914	2,135	1,765	1,815	1,705	1,300	1,657	1,636	1,558	1,414
Gender ~	**Male**	**Level of sharing (direct & indirect) ‡‡**	**49%**	**45%**	**44%**	**38%**	**34%**	**37%**	**34%**	**32%**	**38%**	**36%**	**36%**
		Number reporting sharing	670	646	712	495	466	477	347	402	472	425	386
		Total number answering question	1,379	1,437	1,627	1,302	1,384	1,300	1,015	1,256	1,230	1,183	1,063
	Female	**Level of sharing (direct & indirect) ‡‡**	**55%**	**51%**	**50%**	**44%**	**44%**	**45%**	**40%**	**41%**	**42%**	**46%**	**44%**
		Number reporting sharing	233	235	243	198	185	174	111	160	166	171	154
		Total number answering question	421	464	488	445	417	383	281	395	399	373	347
Age ~	**Under 25**	**Level of sharing (direct & indirect) ‡‡**	**57%**	**49%**	**45%**	**40%**	**45%**	**49%**	**46%**	**45%**	**54%**	**51%**	**43%**
		Number reporting sharing	181	166	175	106	120	106	63	81	65	60	28
		Total number answering question	315	342	391	267	264	215	137	181	121	118	65
	25 to 34	**Level of sharing (direct & indirect) ‡‡**	**51%**	**48%**	**46%**	**41%**	**37%**	**38%**	**35%**	**34%**	**39%**	**38%**	**41%**
		Number reporting sharing	421	414	459	317	283	266	182	217	255	215	194
		Total number answering question	828	869	1,003	780	755	694	522	641	652	561	469
	35 and over	**Level of sharing (direct & indirect) ‡‡**	**45%**	**43%**	**45%**	**39%**	**31%**	**37%**	**34%**	**32%**	**37%**	**37%**	**37%**
		Number reporting sharing	286	285	310	255	226	271	205	250	313	315	319
		Total number answering question	635	658	695	653	730	742	610	793	848	862	872

~ Age and gender not provided by all participants.

‡‡ Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 6: Self-reported hepatitis B vaccine uptake among people who inject drugs by gender and age; England, Wales and Northern Ireland: 2005-2015

Year			2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
All		**Hepatitis B vaccine uptake**	**59%**	**65%**	**66%**	**72%**	**73%**	**74%**	**76%**	**75%**	**72%**	**72%**	**75%**
		Number reporting hepatitis B vaccine	1,835	2,061	2,299	2,259	2,352	2,383	2,094	2,463	2,163	2,126	1,952
		Total number answering question	3,103	3,180	3,491	3,140	3,204	3,199	2,748	3,287	3,011	2,936	2,595
Gender ~	**Male**	**Hepatitis B vaccine uptake**	**60%**	**65%**	**66%**	**72%**	**73%**	**75%**	**76%**	**75%**	**72%**	**72%**	**75%**
		Number reporting hepatitis B vaccine	1,350	1,491	1,701	1,650	1,715	1,783	1,574	1,836	1,588	1,542	1,419
		Total number answering question	2,268	2,290	2,565	2,298	2,344	2,381	2,061	2,440	2,207	2,136	1,895
	Female	**Hepatitis B vaccine uptake**	**58%**	**64%**	**64%**	**72%**	**74%**	**74%**	**76%**	**74%**	**72%**	**73%**	**76%**
		Number reporting hepatitis B vaccine	475	556	574	587	611	577	513	619	566	577	529
		Total number answering question	819	864	892	814	831	782	675	834	784	792	694
Age ~	**Under 25**	**Hepatitis B vaccine uptake**	**58%**	**65%**	**61%**	**69%**	**73%**	**66%**	**76%**	**70%**	**66%**	**67%**	**68%**
		Number reporting hepatitis B vaccine	270	294	305	272	292	223	179	196	117	112	75
		Total number answering question	466	450	500	396	399	338	235	282	178	168	111
	25 to 34	**Hepatitis B vaccine uptake**	**64%**	**69%**	**69%**	**77%**	**77%**	**79%**	**79%**	**78%**	**75%**	**75%**	**76%**
		Number reporting hepatitis B vaccine	869	966	1,060	975	939	946	802	916	799	690	577
		Total number answering question	1,367	1,395	1,544	1,270	1,226	1,191	1,011	1,174	1,067	922	762
	35 and over	**Hepatitis B vaccine uptake**	**54%**	**60%**	**64%**	**69%**	**71%**	**73%**	**74%**	**74%**	**71%**	**72%**	**76%**
		Number reporting hepatitis B vaccine	657	750	874	925	1,025	1,140	1,070	1,288	1,228	1,305	1,286
		Total number answering question	1,212	1,254	1,357	1,345	1,447	1,568	1,438	1,740	1,733	1,813	1,702

~ Age and gender not provided by all participants.

Table 7: Uptake of voluntary confidential testing (VCT) for HIV among people who inject drugs by gender and age; England, Wales and Northern Ireland: 2005-2015

Year			2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
All		**HIV VCT uptake**	**66%**	**69%**	**68%**	**72%**	**75%**	**75%**	**77%**	**79%**	**76%**	**77%**	**79%**
		Number reporting a VCT for HIV	1,992	2,137	2,318	2,224	2,344	2,358	2,047	2,473	2,269	2,234	2,028
		Total number answering question	3,015	3,116	3,410	3,087	3,126	3,129	2,643	3,145	2,986	2,915	2,572
Gender ~	**Male**	**HIV VCT uptake**	**64%**	**68%**	**67%**	**71%**	**74%**	**75%**	**77%**	**78%**	**75%**	**76%**	**78%**
		Number reporting a VCT for HIV	1,418	1,517	1,661	1,605	1,684	1,743	1,521	1,815	1,647	1,612	1,469
		Total number answering question	2,200	2,239	2,494	2,261	2,284	2,333	1,977	2,334	2,187	2,131	1,886
	Female	**HIV VCT uptake**	**71%**	**71%**	**72%**	**75%**	**79%**	**78%**	**79%**	**81%**	**78%**	**79%**	**81%**
		Number reporting a VCT for HIV	564	604	631	599	640	590	517	648	607	616	555
		Total number answering question	796	847	876	797	814	761	655	797	779	776	681
Age ~	**Under 25**	**HIV VCT uptake**	**57%**	**57%**	**57%**	**64%**	**72%**	**65%**	**65%**	**67%**	**64%**	**63%**	**65%**
		Number reporting a VCT for HIV	261	251	280	248	272	209	145	183	112	102	74
		Total number answering question	456	442	490	388	379	323	223	273	176	162	114
	25 to 34	**HIV VCT uptake**	**65%**	**68%**	**66%**	**71%**	**73%**	**73%**	**75%**	**79%**	**75%**	**74%**	**78%**
		Number reporting a VCT for HIV	875	925	1,004	893	878	862	732	880	798	678	583
		Total number answering question	1,338	1,366	1,520	1,265	1,204	1,176	973	1,117	1,059	913	750
	35 and over	**HIV VCT uptake**	**70%**	**74%**	**74%**	**75%**	**77%**	**80%**	**81%**	**80%**	**78%**	**79%**	**80%**
		Number reporting a VCT for HIV	818	914	970	989	1,095	1,220	1,121	1,338	1,338	1,431	1,356
		Total number answering question	1,163	1,230	1,311	1,315	1,413	1,530	1,388	1,667	1,722	1,806	1,688
Among those anti-HIV positive		**Proportion aware of HIV infection**	**47%**	**64%**	**64%**	**64%**	**63%**	**89%**	**88%**	**95%**	**96%**	**85%**	**84%**
		Number aware of their HIV infection	22	25	21	28	27	25	28	37	27	22	21
		Total number answering question	47	39	33	44	43	28	32	39	28	26	25

~ Age and gender not provided by all participants.

Table 8: Uptake of voluntary confidential testing (VCT) for hepatitis C virus (HCV) among people who inject drugs by gender and age; England, Wales and Northern Ireland: 2005-2015

Year			2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
All		**HCV VCT Uptake**	**71%**	**75%**	**74%**	**77%**	**81%**	**82%**	**83%**	**83%**	**82%**	**83%**	**86%**
		Number reporting a VCT for HCV	2,110	2,296	2,493	2,371	2,524	2,530	2,117	2,510	2,483	2,470	2,245
		Total number answering question	2,992	3,071	3,359	3,062	3,100	3,093	2,543	3,014	3,011	2,968	2,616
Gender ~	**Male**	**HCV VCT Uptake**	**69%**	**74%**	**73%**	**76%**	**80%**	**82%**	**83%**	**83%**	**82%**	**84%**	**86%**
		Number reporting a VCT for HCV	1,511	1,642	1,804	1,712	1,824	1,887	1,580	1,848	1,809	1,807	1,644
		Total number answering question	2,179	2,221	2,463	2,241	2,267	2,307	1,901	2,236	2,207	2,161	1,914
	Female	**HCV VCT Uptake**	**74%**	**77%**	**77%**	**80%**	**84%**	**81%**	**84%**	**85%**	**84%**	**82%**	**85%**
		Number reporting a VCT for HCV	588	633	663	636	681	611	527	652	661	655	594
		Total number answering question	795	822	859	793	808	750	630	765	784	798	695
Age ~	**Under 25**	**HCV VCT Uptake**	**64%**	**66%**	**65%**	**68%**	**76%**	**71%**	**75%**	**70%**	**71%**	**68%**	**73%**
		Number reporting a VCT for HCV	289	283	312	261	285	225	162	183	125	116	82
		Total number answering question	454	429	482	382	377	318	216	261	177	170	113
	25 to 34	**HCV VCT Uptake**	**69%**	**75%**	**73%**	**76%**	**80%**	**80%**	**82%**	**84%**	**82%**	**82%**	**83%**
		Number reporting a VCT for HCV	917	1,018	1,091	951	955	925	773	905	872	763	627
		Total number answering question	1,320	1,349	1,492	1,246	1,194	1,158	948	1,083	1,067	935	758
	35 and over	**HCV VCT Uptake**	**74%**	**78%**	**79%**	**80%**	**84%**	**86%**	**86%**	**85%**	**84%**	**86%**	**88%**
		Number reporting a VCT for HCV	866	945	1,028	1,053	1,182	1,306	1,130	1,352	1,460	1,569	1,517
		Total number answering question	1,165	1,217	1,302	1,311	1,401	1,525	1,320	1,593	1,735	1,827	1,722
Among those anti-HCV positive		**Proportion aware of HCV infection**	**52%**	**55%**	**52%**	**50%**	**51%**	**55%**	**51%**	**54%**	**47%**	**52%**	**52%**
		Number aware of their HCV infection	610	639	641	555	631	711	530	703	629	678	619
		Total number answering question	1,167	1,165	1,241	1,112	1,242	1,303	1,035	1,308	1,344	1,297	1,184

~ Age and gender not provided by all participants.

Table 9: Symptoms[§§] of an injection site infection among those who injected during the preceding year by gender and age; England, Wales and Northern Ireland: 2006-2015

Notes:
Survey has asked participants about symptoms at injection sites since 2006.

Year			2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
All		**Symptom[§§] of injection site infection**		**35%**	**38%**	**34%**	**35%**	**35%**	**28%**	**29%**	**28%**	**31%**	**33%**
		Number reporting symptom[§§]		655	787	629	636	528	448	588	536	565	547
		Total number answering question		1,882	2,084	1,870	1,806	1,524	1,600	1,998	1,913	1,820	1,675
Gender [~]	**Male**	**Symptom[§§] of injection site infection**		**33%**	**36%**	**32%**	**33%**	**32%**	**26%**	**29%**	**26%**	**29%**	**31%**
		Number reporting symptom[§§]		464	563	451	446	373	319	430	371	389	382
		Total number answering question		1,403	1,563	1,398	1,353	1,179	1,237	1,503	1,430	1,340	1,245
	Female	**Symptom[§§] of injection site infection**		**40%**	**43%**	**38%**	**42%**	**45%**	**36%**	**32%**	**35%**	**37%**	**38%**
		Number reporting symptom[§§]		187	216	173	186	150	128	157	165	175	164
		Total number answering question		466	501	454	441	330	360	489	473	476	427
Age [~]	**Under 25**	**Symptom[§§] of injection site infection**		**27%**	**35%**	**28%**	**34%**	**34%**	**26%**	**28%**	**20%**	**24%**	**39%**
		Number reporting symptom[§§]		82	115	75	80	67	42	59	28	31	34
		Total number answering question		308	329	271	236	196	162	208	141	129	88
	25 to 34	**Symptom[§§] of injection site infection**		**34%**	**36%**	**30%**	**34%**	**32%**	**25%**	**25%**	**26%**	**29%**	**30%**
		Number reporting symptom[§§]		287	354	239	252	188	159	192	191	190	163
		Total number answering question		835	980	805	744	590	635	768	739	653	548
	35 and over	**Symptom[§§] of injection site infection**		**38%**	**42%**	**40%**	**36%**	**37%**	**31%**	**33%**	**31%**	**33%**	**33%**
		Number reporting symptom[§§]		265	309	293	276	261	236	317	313	341	345
		Total number answering question		696	742	728	758	705	768	963	1,018	1,022	1,032

[~] Age and gender not provided by all participants.
[§§] Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

Table 10: Sexual intercourse (anal or vaginal), number of sexual partners, and condom use during the preceding year; England, Wales and Northern Ireland: 2005-2015

Year			2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
All		**Proportion having sex (anal or vaginal) in preceding year**	**74%**	**74%**	**74%**	**75%**	**74%**	**75%**	**73%**	**73%**	**70%**	**68%**	**66%**
		Number having sex in preceding year	2,274	2,359	2,536	2,326	2,318	2,323	1,997	2,377	2,120	2,001	1,731
		Total number answering question	3,062	3,167	3,430	3,107	3,145	3,116	2,738	3,254	3,034	2,945	2,604
Among those who had (anal or vaginal) sex in the preceding year													
All		**Proportion with two or more partners**	**44%**	**43%**	**42%**	**42%**	**41%**	**44%**	**46%**	**44%**	**41%**	**40%**	**40%**
		Number with two or more partners	961	980	1,023	944	897	961	875	1,021	838	768	676
		Total number answering question	2,196	2,267	2,436	2,250	2,205	2,209	1,921	2,312	2,026	1,917	1,677
Among those with two or more (anal or vaginal) sexual partners in preceding year													
All		**Proportion always using a condom**	**19%**	**19%**	**18%**	**22%**	**20%**	**22%**	**19%**	**17%**	**18%**	**22%**	**22%**
		Number always using a condom	180	169	181	194	168	196	150	153	128	143	124
		Total number answering question	935	912	979	889	844	878	777	924	705	657	576
Gender ~	**Male**	**Proportion always using a condom**	**18%**	**18%**	**17%**	**21%**	**17%**	**22%**	**19%**	**15%**	**18%**	**22%**	**20%**
		Number always using a condom	134	130	131	145	108	157	118	111	101	117	87
		Total number answering question	748	714	776	688	648	698	632	723	563	529	438
	Female	**Proportion always using a condom**	**24%**	**20%**	**23%**	**25%**	**31%**	**21%**	**22%**	**21%**	**19%**	**21%**	**27%**
		Number always using a condom	44	38	43	48	59	36	32	42	26	26	37
		Total number answering question	184	192	191	189	191	169	143	196	138	126	137
Age ~	**Under 25**	**Proportion always using a condom**	**14%**	**18%**	**14%**	**19%**	**17%**	**18%**	**14%**	**13%**	**7.4%**	**12%**	**17%**
		Number always using a condom	29	34	24	28	28	26	14	16	6	7	7
		Total number answering question	212	190	176	144	167	147	102	122	81	60	42
	25 to 34	**Proportion always using a condom**	**17%**	**19%**	**18%**	**17%**	**18%**	**22%**	**17%**	**14%**	**16%**	**17%**	**19%**
		Number always using a condom	75	84	91	76	66	84	58	57	49	46	40
		Total number answering question	453	454	507	436	368	381	340	413	304	264	214
	35 and over	**Proportion always using a condom**	**27%**	**19%**	**21%**	**28%**	**23%**	**26%**	**23%**	**21%**	**23%**	**27%**	**24%**
		Number always using a condom	68	47	57	78	68	84	72	77	72	89	77
		Total number answering question	251	248	277	275	290	327	319	368	315	326	316

~ Age and gender not provided by all participants.

Table 11: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; England: 2005-2015

Notes: Behavioural data have not been collected in all years. In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2005	2006	2007	2008	2009		2010		2011	2012	2013	2014	2015
Sample type	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*DBS*	*Oral fluid**	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*
Anti-HIV Prevalence †	**1.6%**	**1.3%**	**1.2%**	**1.5%**	**1.6%**		**1.2%**		**1.3%**	**1.4%**	**1.2%**	**1.0%**	**1.0%**
Number of samples anti-HIV positive	45	39	37	44	46		35		32	43	32	27	23
Total number of samples collected	2,839	2,893	3,085	2,893	2,962		2,899		2,485	2,982	2,782	2,667	2,307
Anti-HBc Prevalence ††	**28%**	**29%**	**22%**	**19%**	**18%**		**17%**		**16%**	**18%**	**17%**	**15%**	**14%**
Proportion of samples anti-HBc positive	21%	22%	16%	14%	15%	11%	16%	16%	16%	18%	17%	15%	14%
Number of samples anti-HBc positive	589	634	506	402	355	59	142	317	404	528	481	404	319
Total number of samples collected	2,838	2,893	3,085	2,892	2,426	536	881	2,018	2,485	2,982	2,782	2,667	2,307
Anti-HCV Prevalence †††	**48%**	**46%**	**46%**	**44%**	**49%**		**49%**		**45%**	**49%**	**50%**	**50%**	**52%**
Proportion of samples anti-HCV positive	44%	43%	42%	41%	45%	47%	45%	49%	45%	49%	50%	50%	52%
Number of samples anti-HCV positive	1,251	1,233	1,292	1,177	1,092	252	395	991	1,115	1,466	1,398	1,345	1,191
Total number of samples collected	2,838	2,893	3,085	2,893	2,426	536	881	2,018	2,485	2,982	2,782	2,667	2,307
Hepatitis B vaccine uptake	**60%**	**65%**	**66%**	**72%**	**73%**		**75%**		**77%**	**75%**	**71%**	**72%**	**75%**
Number reporting hepatitis B vaccine uptake	1,655	1,838	1,982	2,039	2,117		2,120		1,844	2,169	1,903	1,815	1,644
Total number answering question	2,772	2,839	3,008	2,828	2,893		2,816		2,408	2,886	2,662	2,532	2,198
HCV VCT uptake	**71%**	**75%**	**75%**	**77%**	**81%**		**83%**		**83%**	**83%**	**82%**	**83%**	**86%**
Number reporting a VCT for HCV	1,891	2,050	2,174	2,114	2,270		2,246		1,842	2,203	2,181	2,118	1,902
Total number answering question	2,670	2,745	2,906	2,757	2,794		2,719		2,229	2,654	2,664	2,561	2,217
Proportion aware of HCV infection	**52%**	**54%**	**52%**	**49%**	**51%**		**55%**		**50%**	**54%**	**47%**	**52%**	**53%**
Number aware of their HCV infection	573	590	594	506	596		667		473	650	570	596	544
Total number answering question	1,098	1,093	1,140	1,029	1,169		1,215		937	1,195	1,211	1,140	1,034
HIV VCT uptake	**67%**	**69%**	**68%**	**72%**	**74%**		**75%**		**77%**	**78%**	**75%**	**76%**	**78%**
Number reporting a VCT for HIV	1,795	1,914	2,014	2,000	2,090		2,076		1,780	2,163	1,996	1,898	1,706
Total number answering question	2,690	2,786	2,941	2,786	2,812		2,756		2,321	2,768	2,645	2,512	2,176
Among those who had injected in preceding year													
Symptom§§ of injection site infection		**36%**	**39%**	**34%**	**36%**		**35%**		**27%**	**30%**	**28%**	**31%**	**32%**
Number reporting symptom§§		610	708	579	593		489		385	522	473	479	446
Total number answering question		1,718	1,825	1,716	1,646		1,381		1,416	1,766	1,703	1,569	1,413
Among those who had injected in preceding four weeks													
Level of direct sharing ‡	**28%**	**23%**	**24%**	**19%**	**19%**		**21%**		**17%**	**14%**	**16%**	**16%**	**17%**
Number reporting direct sharing	475	413	449	316	315		337		202	216	228	220	198
Total number answering question	1,671	1,766	1,878	1,683	1,668		1,576		1,159	1,494	1,462	1,352	1,187
Level of sharing (direct & indirect) ‡‡	**50%**	**47%**	**46%**	**39%**	**36%**		**39%**		**36%**	**35%**	**39%**	**38%**	**38%**
Number reporting sharing	839	829	888	649	609		614		415	521	570	522	453
Total number answering question	1,668	1,770	1,918	1,650	1,673		1,580		1,154	1,492	1,474	1,366	1,192
Proportion injecting crack		**37%**	**37%**	**37%**	**31%**		**31%**		**35%**	**38%**	**39%**	**43%**	**51%**
Number reporting crack injection		651	708	630	519		489		400	566	588	596	616
Total number answering question		1,747	1,902	1,720	1,665		1,581		1,159	1,509	1,502	1,379	1,213
Proportion injecting into their groin		**36%**	**33%**	**32%**	**36%**		**35%**		**35%**	**35%**	**39%**	**38%**	**38%**
Number reporting groin injection		597	619	549	597		546		415	527	587	527	456
Total number answering question		1,662	1,879	1,691	1,639		1,565		1,170	1,523	1,515	1,388	1,216
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	**19%**	**18%**	**19%**	**22%**	**20%**		**21%**		**18%**	**17%**	**18%**	**22%**	**21%**
Number always using a condom	163	146	162	180	154		163		124	146	111	122	102
Total number answering question	845	803	839	816	768		770		698	843	624	565	481

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

‡ Sharing of needles and syringes in preceding four weeks.

‡‡ Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 12: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; PHE Region North: 2005-2015

Notes: Behavioural data have not been collected in all years. In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2005	2006	2007	2008	2009		2010		2011	2012	2013	2014	2015
Sample type	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*DBS*	*Oral fluid**	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*
Anti-HIV Prevalence †	**0.77%**	**0.62%**	**0.55%**	**1.4%**	**1.5%**		**0.80%**		**0.77%**	**0.93%**	**0.20%**	**0.10%**	**0.25%**
Number of samples anti-HIV positive	7	6	5	12	13		9		7	10	2	1	2
Total number of samples collected	915	974	903	850	849		1,120		911	1,072	980	1,004	799
Anti-HBc Prevalence ††	**27%**	**30%**	**24%**	**19%**	**17%**		**19%**		**18%**	**17%**	**19%**	**15%**	**14%**
Proportion of samples anti-HBc positive	20%	23%	18%	14%	14%	10%	11%	21%	18%	17%	19%	15%	14%
Number of samples anti-HBc positive	186	220	160	121	96	17	45	151	168	182	190	155	113
Total number of samples collected	915	974	903	849	683	166	394	726	911	1,072	980	1,004	799
Anti-HCV Prevalence †††	**47%**	**49%**	**46%**	**47%**	**49%**		**51%**		**49%**	**52%**	**54%**	**52%**	**56%**
Proportion of samples anti-HCV positive	43%	45%	43%	44%	45%	45%	38%	56%	49%	52%	54%	52%	56%
Number of samples anti-HCV positive	397	443	385	371	310	75	151	409	450	555	525	524	448
Total number of samples collected	915	974	903	850	683	166	394	726	911	1,072	980	1,004	799
Hepatitis B vaccine uptake	**64%**	**72%**	**73%**	**78%**	**79%**		**78%**		**80%**	**78%**	**74%**	**73%**	**80%**
Number reporting hepatitis B vaccine uptake	573	687	641	651	665		861		693	815	699	701	609
Total number answering question	891	959	875	831	837		1,097		869	1,042	942	960	762
HCV VCT uptake	**67%**	**73%**	**74%**	**77%**	**81%**		**86%**		**85%**	**83%**	**80%**	**79%**	**86%**
Number reporting a VCT for HCV	575	672	618	619	648		902		667	797	745	757	656
Total number answering question	861	920	840	802	804		1,049		788	960	929	958	762
Proportion aware of HCV infection	**41%**	**40%**	**40%**	**49%**	**48%**		**52%**		**49%**	**52%**	**44%**	**51%**	**52%**
Number aware of their HCV infection	146	154	131	157	160		256		182	233	201	224	205
Total number answering question	352	389	329	320	335		493		370	448	457	443	395
HIV VCT uptake	**59%**	**63%**	**65%**	**68%**	**71%**		**75%**		**77%**	**76%**	**70%**	**70%**	**77%**
Number reporting a VCT for HIV	508	594	555	554	572		803		637	763	652	656	585
Total number answering question	859	943	849	812	810		1,067		828	1,004	928	939	759
Among those who had injected in preceding year													
Symptom§§ of injection site infection		**32%**	**36%**	**31%**	**36%**		**35%**		**29%**	**29%**	**26%**	**31%**	**30%**
Number reporting symptom§§		179	189	147	172		182		135	180	143	170	138
Total number answering question		567	527	470	483		524		469	623	541	553	457
Among those who had injected in preceding four weeks													
Level of direct sharing ‡	**29%**	**23%**	**24%**	**18%**	**17%**		**20%**		**14%**	**15%**	**17%**	**16%**	**15%**
Number reporting direct sharing	161	138	134	83	83		123		54	81	81	75	60
Total number answering question	555	609	566	473	490		616		388	528	482	476	393
Level of sharing (direct & indirect) ‡‡	**50%**	**44%**	**42%**	**36%**	**30%**		**36%**		**34%**	**35%**	**39%**	**39%**	**36%**
Number reporting sharing	275	267	242	169	148		223		133	187	190	186	141
Total number answering question	553	611	574	471	493		613		386	529	484	482	394
Proportion injecting crack		**38%**	**36%**	**34%**	**22%**		**24%**		**26%**	**24%**	**34%**	**32%**	**43%**
Number reporting crack injection		232	207	165	108		146		99	132	168	155	173
Total number answering question		611	574	483	488		612		387	540	498	487	399
Proportion injecting into their groin		**40%**	**33%**	**35%**	**38%**		**36%**		**41%**	**38%**	**45%**	**41%**	**45%**
Number reporting groin injection		225	184	170	181		218		159	207	227	199	180
Total number answering question		564	564	481	482		607		391	540	502	490	399
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	**17%**	**17%**	**19%**	**16%**	**16%**		**23%**		**17%**	**17%**	**15%**	**18%**	**23%**
Number always using a condom	48	43	48	38	38		66		43	53	34	32	35
Total number answering question	284	258	247	232	244		283		260	304	222	182	155

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

‡ Sharing of needles and syringes in preceding four weeks.

‡‡ Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 13: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; PHE Region Midlands & East: 2005-2015

Notes: Behavioural data have not been collected in all years. In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2005	2006	2007	2008	2009		2010		2011	2012	2013	2014	2015
Sample type	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*DBS*	*Oral fluid**	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*
Anti-HIV Prevalence †	**1.2%**	**0.63%**	**0.46%**	**0.73%**	**0.68%**		**0.31%**		**1.1%**	**1.1%**	**1.3%**	**1.0%**	**0.80%**
Number of samples anti-HIV positive	5	3	3	6	5		2		7	7	12	8	5
Total number of samples collected	402	478	655	818	738		639		635	654	910	773	626
Anti-HBc Prevalence ††	**23%**	**16%**	**8.8%**	**10%**	**8.4%**		**10%**		**11%**	**10%**	**11%**	**10%**	**10%**
Proportion of samples anti-HBc positive	17%	12%	6.6%	7.2%	7.8%	4.3%	7.6%	10%	11%	10%	11%	10%	10%
Number of samples anti-HBc positive	70	56	43	59	38	11	13	46	68	64	99	74	60
Total number of samples collected	402	478	655	818	485	253	171	468	635	654	910	773	626
Anti-HCV Prevalence †††	**46%**	**30%**	**31%**	**31%**	**41%**		**35%**		**35%**	**40%**	**45%**	**41%**	**43%**
Proportion of samples anti-HCV positive	43%	28%	29%	29%	36%	44%	35%	35%	35%	40%	45%	41%	43%
Number of samples anti-HCV positive	171	134	187	236	176	112	59	162	221	262	414	318	267
Total number of samples collected	402	478	655	818	485	253	171	468	635	654	910	773	626
Hepatitis B vaccine uptake	**64%**	**63%**	**67%**	**71%**	**74%**		**70%**		**77%**	**75%**	**69%**	**72%**	**71%**
Number reporting hepatitis B vaccine uptake	250	297	431	567	539		443		475	482	595	529	429
Total number answering question	391	473	644	799	731		632		618	641	866	731	602
HCV VCT uptake	**73%**	**65%**	**71%**	**74%**	**79%**		**74%**		**80%**	**78%**	**80%**	**82%**	**84%**
Number reporting a VCT for HCV	276	293	434	569	563		453		471	462	702	608	507
Total number answering question	380	449	614	770	713		614		589	589	875	743	604
Proportion aware of HCV infection	**52%**	**36%**	**39%**	**37%**	**45%**		**49%**		**39%**	**46%**	**44%**	**49%**	**55%**
Number aware of their HCV infection	79	43	65	73	119		98		74	100	155	133	119
Total number answering question	153	119	167	200	262		199		188	219	351	270	218
HIV VCT uptake	**66%**	**61%**	**62%**	**70%**	**71%**		**65%**		**74%**	**72%**	**73%**	**74%**	**74%**
Number reporting a VCT for HIV	254	278	386	548	507		399		444	447	633	536	433
Total number answering question	383	459	620	787	719		611		602	618	863	723	586
Among those who had injected in preceding year													
Symptom§§ of injection site infection		**31%**	**37%**	**29%**	**28%**		**29%**		**24%**	**26%**	**27%**	**27%**	**31%**
Number reporting symptom§§		94	158	153	125		94		87	106	167	137	128
Total number answering question		305	425	528	439		324		361	414	619	502	411
Among those who had injected in preceding four weeks													
Level of direct sharing ‡	**26%**	**21%**	**20%**	**18%**	**16%**		**18%**		**14%**	**10%**	**14%**	**14%**	**15%**
Number reporting direct sharing	70	67	85	92	73		69		41	35	77	63	53
Total number answering question	270	326	434	521	446		376		283	352	551	441	360
Level of sharing (direct & indirect) ‡‡	**53%**	**45%**	**41%**	**37%**	**36%**		**33%**		**32%**	**29%**	**34%**	**33%**	**33%**
Number reporting sharing	144	148	184	181	162		123		91	103	189	149	119
Total number answering question	270	329	445	487	446		376		283	351	555	445	361
Proportion injecting crack		**33%**	**36%**	**26%**	**25%**		**29%**		**32%**	**41%**	**37%**	**37%**	**45%**
Number reporting crack injection		108	161	142	113		110		90	147	207	165	166
Total number answering question		329	451	540	445		378		284	356	561	446	371
Proportion injecting into their groin		**34%**	**36%**	**34%**	**39%**		**32%**		**31%**	**39%**	**38%**	**38%**	**32%**
Number reporting groin injection		109	160	183	173		119		90	142	219	173	118
Total number answering question		325	447	531	439		372		286	361	572	454	369
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	**16%**	**18%**	**16%**	**22%**	**18%**		**21%**		**19%**	**14%**	**17%**	**25%**	**22%**
Number always using a condom	23	26	31	54	34		38		31	27	36	43	31
Total number answering question	144	146	193	247	194		179		165	189	217	172	139

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

‡ Sharing of needles and syringes in preceding four weeks.

‡‡ Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 14: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; PHE Region South: 2005-2015

Notes: Behavioural data have not been collected in all years. In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2005	2006	2007	2008	2009		2010		2011	2012	2013	2014	2015
Sample type	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*DBS*	*Oral fluid**	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*
Anti-HIV Prevalence †	**1.5%**	**0.71%**	**0.64%**	**0.74%**	**0.51%**		**0.83%**		**1.1%**	**0.73%**	**0.19%**	**0%**	**1.7%**
Number of samples anti-HIV positive	13	6	6	5	4		6		7	5	1	0	9
Total number of samples collected	894	848	933	679	784		722		659	683	515	504	530
Anti-HBc Prevalence ††	**25%**	**25%**	**20%**	**21%**	**18%**		**13%**		**15%**	**18%**	**17%**	**16%**	**14%**
Proportion of samples anti-HBc positive	19%	19%	15%	16%	12%	26%	0%	13%	15%	18%	17%	16%	14%
Number of samples anti-HBc positive	167	157	143	108	81	31	0	94	100	123	88	79	74
Total number of samples collected	893	848	933	679	667	117	14	708	659	683	515	504	530
Anti-HCV Prevalence †††	**40%**	**42%**	**42%**	**46%**	**48%**		**49%**		**47%**	**45%**	**46%**	**54%**	**53%**
Proportion of samples anti-HCV positive	36%	38%	39%	42%	43%	56%	29%	49%	47%	45%	46%	54%	53%
Number of samples anti-HCV positive	325	324	364	285	287	65	4	349	309	309	236	273	281
Total number of samples collected	893	848	933	679	667	117	14	708	659	683	515	504	530
Hepatitis B vaccine uptake	**51%**	**60%**	**58%**	**70%**	**69%**		**76%**		**75%**	**72%**	**69%**	**72%**	**74%**
Number reporting hepatitis B vaccine uptake	448	498	529	467	531		538		484	476	339	347	372
Total number answering question	873	834	910	665	771		705		647	662	492	484	505
HCV VCT uptake	**68%**	**75%**	**72%**	**75%**	**80%**		**82%**		**83%**	**82%**	**84%**	**88%**	**87%**
Number reporting a VCT for HCV	573	608	644	497	605		574		511	514	419	431	447
Total number answering question	844	815	890	659	755		698		616	624	496	489	513
Proportion aware of HCV infection	**54%**	**60%**	**55%**	**44%**	**46%**		**54%**		**57%**	**54%**	**47%**	**54%**	**49%**
Number aware of their HCV infection	155	174	178	115	144		175		154	140	94	126	119
Total number answering question	286	292	325	260	312		322		272	257	202	235	244
HIV VCT uptake	**69%**	**70%**	**68%**	**72%**	**77%**		**78%**		**79%**	**82%**	**80%**	**80%**	**82%**
Number reporting a VCT for HIV	590	574	617	478	577		553		504	528	394	386	410
Total number answering question	860	820	905	662	754		709		634	646	492	483	500
Among those who had injected in preceding year													
Symptom§§ of injection site infection		**40%**	**40%**	**39%**	**40%**		**40%**		**26%**	**28%**	**26%**	**32%**	**38%**
Number reporting symptom§§		229	237	178	193		162		119	120	90	110	138
Total number answering question		572	592	460	486		406		466	436	349	349	366
Among those who had injected in preceding four weeks													
Level of direct sharing ‡	**29%**	**26%**	**27%**	**21%**	**24%**		**25%**		**22%**	**17%**	**17%**	**20%**	**22%**
Number reporting direct sharing	157	147	161	97	118		107		86	64	48	65	67
Total number answering question	536	566	607	463	493		431		392	381	285	319	310
Level of sharing (direct & indirect) ‡‡	**50%**	**51%**	**51%**	**45%**	**44%**		**47%**		**41%**	**39%**	**48%**	**47%**	**47%**
Number reporting sharing	266	286	316	210	219		203		161	150	139	150	149
Total number answering question	535	564	622	467	497		436		389	381	291	322	314
Proportion injecting crack		**34%**	**32%**	**45%**	**37%**		**37%**		**41%**	**42%**	**44%**	**65%**	**63%**
Number reporting crack injection		192	200	210	183		160		160	160	129	209	201
Total number answering question		569	622	469	496		438		391	379	296	324	318
Proportion injecting into their groin		**38%**	**33%**	**34%**	**36%**		**36%**		**33%**	**30%**	**35%**	**37%**	**40%**
Number reporting groin injection		202	199	158	178		157		131	116	102	117	127
Total number answering question		538	606	459	490		436		394	386	294	320	321
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	**19%**	**18%**	**16%**	**18%**	**21%**		**17%**		**18%**	**11%**	**15%**	**15%**	**19%**
Number always using a condom	51	48	44	37	47		39		38	25	17	21	23
Total number answering question	262	273	269	203	227		231		206	223	113	136	119

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

‡ Sharing of needles and syringes in preceding four weeks.

‡‡ Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 15: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; PHE & NUTS Region London: 2005-2015

Notes: Behavioural data have not been collected in all years. In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2005	2006	2007	2008	2009	2010		2011	2012	2013	2014	2015
Sample type	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*
Anti-HIV Prevalence †	**3.2%**	**4.0%**	**3.9%**	**3.8%**	**4.1%**	**4.3%**		**3.9%**	**3.7%**	**4.5%**	**4.7%**	**2.0%**
Number of samples anti-HIV positive	20	24	23	21	24	18		11	21	17	18	7
Total number of samples collected	628	593	594	546	591	418		280	573	377	386	352
Anti-HBc Prevalence ††	**35%**	**45%**	**36%**	**28%**	**32%**	**33%**		**24%**	**28%**	**28%**	**25%**	**20%**
Proportion of samples anti-HBc positive	26%	34%	27%	21%	24%	28%	22%	24%	28%	28%	25%	20%
Number of samples anti-HBc positive	166	201	160	114	140	84	26	68	159	104	96	72
Total number of samples collected	628	593	594	546	591	302	116	280	573	377	386	352
Anti-HCV Prevalence †††	**62%**	**61%**	**65%**	**57%**	**59%**	**64%**		**48%**	**59%**	**59%**	**60%**	**55%**
Proportion of samples anti-HCV positive	57%	56%	60%	52%	54%	60%	61%	48%	59%	59%	60%	55%
Number of samples anti-HCV positive	358	332	356	285	319	181	71	135	340	223	230	195
Total number of samples collected	628	593	594	546	591	302	116	280	573	377	386	352
Hepatitis B vaccine uptake	**62%**	**62%**	**66%**	**66%**	**69%**	**73%**		**70%**	**73%**	**75%**	**67%**	**71%**
Number reporting hepatitis B vaccine uptake	384	356	381	354	382	278		192	396	270	238	234
Total number answering question	617	573	579	533	554	382		274	541	362	357	329
HCV VCT uptake	**80%**	**85%**	**85%**	**82%**	**87%**	**89%**		**82%**	**89%**	**87%**	**87%**	**86%**
Number reporting a VCT for HCV	467	477	478	429	454	317		193	430	315	322	292
Total number answering question	585	561	562	526	522	358		236	481	364	371	338
Proportion aware of HCV infection	**63%**	**75%**	**69%**	**65%**	**67%**	**69%**		**59%**	**65%**	**60%**	**59%**	**57%**
Number aware of their HCV infection	193	219	220	161	173	138		63	177	120	113	101
Total number answering question	307	293	319	249	260	201		107	271	201	192	177
HIV VCT uptake	**75%**	**83%**	**80%**	**80%**	**82%**	**87%**		**76%**	**85%**	**88%**	**87%**	**84%**
Number reporting a VCT for HIV	443	468	456	420	434	321		195	425	317	320	278
Total number answering question	588	564	567	525	529	369		257	500	362	367	331
Among those who had injected in preceding year												
Symptom§§ of injection site infection		**39%**	**44%**	**39%**	**43%**	**40%**		**37%**	**40%**	**38%**	**38%**	**23%**
Number reporting symptom§§		108	124	101	103	51		44	116	73	62	42
Total number answering question		274	281	258	238	127		120	293	194	165	179
Among those who had injected in preceding four weeks												
Level of direct sharing ‡	**28%**	**23%**	**25%**	**19%**	**17%**	**25%**		**22%**	**15%**	**15%**	**15%**	**15%**
Number reporting direct sharing	87	61	69	44	41	38		21	36	22	17	18
Total number answering question	310	265	271	226	239	153		96	233	144	116	124
Level of sharing (direct & indirect) ‡‡	**50%**	**48%**	**53%**	**40%**	**34%**	**42%**		**31%**	**35%**	**36%**	**32%**	**36%**
Number reporting sharing	154	128	146	89	80	65		30	81	52	37	44
Total number answering question	310	266	277	225	237	155		96	231	144	117	123
Proportion injecting crack		**50%**	**55%**	**50%**	**49%**	**48%**		**53%**	**54%**	**57%**	**55%**	**61%**
Number reporting crack injection		119	140	113	115	73		51	127	84	67	76
Total number answering question		238	255	228	236	153		97	234	147	122	125
Proportion injecting into their groin		**26%**	**29%**	**17%**	**29%**	**35%**		**35%**	**26%**	**27%**	**31%**	**24%**
Number reporting groin injection		61	76	38	65	52		35	62	39	38	31
Total number answering question		235	262	220	228	150		99	236	147	124	127
Among those with two or more (anal or vaginal) sexual partners in preceding year												
Proportion always using a condom	**26%**	**23%**	**30%**	**38%**	**34%**	**26%**		**18%**	**32%**	**33%**	**35%**	**19%**
Number always using a condom	41	29	39	51	35	20		12	41	24	26	13
Total number answering question	155	126	130	134	103	77		67	127	72	75	68

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

‡ Sharing of needles and syringes in preceding four weeks.

‡‡ Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 16: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region East of England: 2005-2015

Notes: Behavioural data have not been collected in all years. In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
Sample type	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*
Anti-HIV Prevalence †	**2.2%**	**0.58%**	**0.91%**	**0.84%**	**0.75%**	**0%**	**0.65%**	**0%**	**1.7%**	**0%**	**0%**
Number of samples anti-HIV positive	4	1	1	2	1	0	1	0	3	0	0
Total number of samples collected	179	172	110	238	134	119	153	145	176	163	241
Anti-HBc Prevalence ††	**32%**	**24%**	**15%**	**16%**	**18%**	**10%**	**18%**	**10%**	**11%**	**13%**	**10%**
Proportion of samples anti-HBc positive	24%	18%	11%	12%	13%	7.6%	18%	10%	11%	13%	10%
Number of samples anti-HBc positive	43	31	12	29	18	9	27	14	19	22	23
Total number of samples collected	179	172	110	238	134	119	153	145	176	163	241
Anti-HCV Prevalence †††	**45%**	**28%**	**38%**	**34%**	**48%**	**34%**	**41%**	**37%**	**46%**	**39%**	**46%**
Proportion of samples anti-HCV positive	41%	26%	35%	32%	44%	31%	41%	37%	46%	39%	46%
Number of samples anti-HCV positive	74	44	38	75	59	37	63	53	81	63	110
Total number of samples collected	179	172	110	238	134	119	153	145	176	163	241
Hepatitis B vaccine uptake	**61%**	**64%**	**61%**	**73%**	**79%**	**63%**	**74%**	**74%**	**65%**	**72%**	**69%**
Number reporting hepatitis B vaccine uptake	106	109	63	171	104	75	109	106	106	103	158
Total number answering question	173	170	104	235	132	119	148	143	163	143	230
HCV VCT uptake	**73%**	**68%**	**76%**	**76%**	**85%**	**74%**	**88%**	**69%**	**80%**	**77%**	**76%**
Number reporting a VCT for HCV	124	110	74	170	111	86	128	92	137	119	175
Total number answering question	170	162	98	223	131	117	146	134	171	154	229
Proportion aware of HCV infection	**66%**	**55%**	**44%**	**37%**	**58%**	**53%**	**57%**	**33%**	**47%**	**47%**	**49%**
Number aware of their HCV infection	45	22	16	22	31	18	31	15	32	25	39
Total number answering question	68	40	36	59	53	34	54	45	68	53	79
HIV VCT uptake	**65%**	**68%**	**69%**	**74%**	**76%**	**70%**	**84%**	**70%**	**77%**	**73%**	**65%**
Number reporting a VCT for HIV	112	112	67	169	100	81	123	97	132	110	143
Total number answering question	171	165	97	228	131	115	147	138	171	150	221
Among those who had injected in preceding year											
Symptom§§ of injection site infection		**27%**	**48%**	**34%**	**25%**	**34%**	**23%**	**24%**	**27%**	**25%**	**37%**
Number reporting symptom§§		25	24	42	17	21	18	22	34	20	60
Total number answering question		93	50	124	69	61	78	92	127	79	161
Among those who had injected in preceding four weeks											
Level of direct sharing ‡	**28%**	**21%**	**21%**	**22%**	**27%**	**29%**	**15%**	**5.5%**	**12%**	**12%**	**16%**
Number reporting direct sharing	20	14	11	23	12	24	8	4	11	7	23
Total number answering question	72	66	53	106	45	83	52	73	93	60	142
Level of sharing (direct & indirect) ‡‡	**54%**	**42%**	**48%**	**42%**	**42%**	**45%**	**35%**	**22%**	**38%**	**31%**	**39%**
Number reporting sharing	39	28	26	46	19	37	18	16	36	19	56
Total number answering question	72	67	54	109	45	83	52	73	94	61	142
Proportion injecting crack		**22%**	**35%**	**21%**	**24%**	**24%**	**40%**	**39%**	**38%**	**43%**	**46%**
Number reporting crack injection		15	19	23	11	20	21	28	36	26	68
Total number answering question		68	54	109	46	82	53	72	96	61	147
Proportion injecting into their groin		**28%**	**21%**	**30%**	**33%**	**17%**	**32%**	**37%**	**38%**	**34%**	**36%**
Number reporting groin injection		18	12	32	15	13	17	27	38	21	52
Total number answering question		65	57	106	46	78	53	73	99	62	146
Among those with two or more (anal or vaginal) sexual partners in preceding year											
Proportion always using a condom	**21%**	**17%**	**18%**	**36%**	**17%**	**42%**	**26%**	**25%**	**7.7%**	**26%**	**20%**
Number always using a condom	12	8	6	27	6	16	10	11	4	8	12
Total number answering question	57	47	34	74	35	38	38	44	52	31	60

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

‡ Sharing of needles and syringes in preceding four weeks.

‡‡ Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 17: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region South East: 2005-2015

Notes: Behavioural data have not been collected in all years. In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2005	2006	2007	2008	2009		2010		2011	2012	2013	2014	2015
Sample type	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*DBS*	*Oral fluid**	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*
Anti-HIV Prevalence †	**1.3%**	**0.75%**	**1.1%**	**0.88%**	**0.76%**		**1.2%**		**1.8%**	**1.0%**	**0.46%**	**0%**	**1.8%**
Number of samples anti-HIV positive	6	3	6	4	4		5		6	3	1	0	5
Total number of samples collected	476	400	548	452	524		428		337	300	217	237	271
Anti-HBc Prevalence ††	**28%**	**24%**	**19%**	**24%**	**18%**		**17%**		**19%**	**25%**	**18%**	**20%**	**18%**
Proportion of samples anti-HBc positive	21%	18%	15%	18%	12%	26%	0%	17%	19%	25%	18%	20%	18%
Number of samples anti-HBc positive	100	73	80	80	49	31	0	71	64	74	40	48	48
Total number of samples collected	476	400	548	452	407	117	14	414	337	300	217	237	271
Anti-HCV Prevalence †††	**46%**	**41%**	**47%**	**51%**	**52%**		**57%**		**54%**	**58%**	**54%**	**58%**	**58%**
Proportion of samples anti-HCV positive	42%	38%	43%	46%	47%	56%	29%	57%	54%	58%	54%	58%	58%
Number of samples anti-HCV positive	201	152	238	210	191	65	4	238	181	174	118	137	158
Total number of samples collected	476	400	548	452	407	117	14	414	337	300	217	237	271
Hepatitis B vaccine uptake	**46%**	**56%**	**57%**	**70%**	**71%**		**75%**		**77%**	**73%**	**74%**	**73%**	**73%**
Number reporting hepatitis B vaccine uptake	216	221	302	308	364		314		256	218	151	168	185
Total number answering question	466	392	532	442	512		420		332	297	204	229	255
HCV VCT uptake	**66%**	**73%**	**72%**	**77%**	**80%**		**81%**		**85%**	**83%**	**87%**	**90%**	**88%**
Number reporting a VCT for HCV	295	286	373	337	405		344		272	235	181	209	229
Total number answering question	450	390	518	437	504		424		320	282	208	231	260
Proportion aware of HCV infection	**56%**	**59%**	**57%**	**47%**	**44%**		**53%**		**59%**	**60%**	**50%**	**50%**	**44%**
Number aware of their HCV infection	98	82	121	90	99		121		97	90	53	60	61
Total number answering question	174	138	214	193	225		227		165	151	106	120	138
HIV VCT uptake	**68%**	**69%**	**69%**	**74%**	**78%**		**77%**		**83%**	**82%**	**81%**	**83%**	**81%**
Number reporting a VCT for HIV	312	270	363	326	393		330		270	237	170	185	202
Total number answering question	462	390	529	441	504		427		326	289	210	224	249
Among those who had injected in preceding year													
Symptom§§ of injection site infection		**42%**	**38%**	**39%**	**40%**		**41%**		**25%**	**31%**	**28%**	**34%**	**34%**
Number reporting symptom§§		121	131	121	129		107		62	69	43	54	62
Total number answering question		288	346	311	319		258		247	222	153	159	183
Among those who had injected in preceding four weeks													
Level of direct sharing ‡	**27%**	**26%**	**28%**	**21%**	**26%**		**21%**		**21%**	**14%**	**14%**	**18%**	**21%**
Number reporting direct sharing	75	71	99	67	85		59		47	28	19	27	35
Total number answering question	282	276	354	315	328		277		220	201	137	152	165
Level of sharing (direct & indirect) ‡‡	**47%**	**56%**	**55%**	**48%**	**47%**		**44%**		**37%**	**34%**	**41%**	**37%**	**45%**
Number reporting sharing	132	155	199	154	154		125		81	67	57	57	74
Total number answering question	282	277	361	318	329		282		219	199	138	154	166
Proportion injecting crack		**42%**	**37%**	**49%**	**40%**		**43%**		**46%**	**46%**	**54%**	**65%**	**60%**
Number reporting crack injection		118	131	155	132		121		102	92	75	102	100
Total number answering question		280	357	318	329		282		222	199	140	157	166
Proportion injecting into their groin		**34%**	**31%**	**33%**	**38%**		**36%**		**33%**	**28%**	**29%**	**37%**	**37%**
Number reporting groin injection		92	110	104	122		101		73	56	41	57	63
Total number answering question		269	350	312	325		283		223	202	139	155	169
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	**15%**	**12%**	**18%**	**17%**	**25%**		**15%**		**21%**	**12%**	**10%**	**15%**	**18%**
Number always using a condom	20	16	27	24	40		20		20	11	4	9	10
Total number answering question	137	135	151	139	159		136		97	93	40	61	57

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

‡ Sharing of needles and syringes in preceding four weeks.

‡‡ Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 18: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region South West: 2005-2015

Notes: Behavioural data have not been collected in all years. In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
Sample type	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*
Anti-HIV Prevalence †	**1.7%**	**0.67%**	**0%**	**0.44%**	**0%**	**0.34%**	**0.31%**	**0.52%**	**0%**	**0%**	**1.5%**
Number of samples anti-HIV positive	7	3	0	1	0	1	1	2	0	0	4
Total number of samples collected	418	448	385	227	260	294	322	383	298	267	259
Anti-HBc Prevalence ††	**21%**	**25%**	**22%**	**16%**	**16%**	**7.8%**	**11%**	**13%**	**16%**	**12%**	**10%**
Proportion of samples anti-HBc positive	16%	19%	16%	12%	12%	7.8%	11%	13%	16%	12%	10%
Number of samples anti-HBc positive	67	84	63	28	32	23	36	49	48	31	26
Total number of samples collected	417	448	385	227	260	294	322	383	298	267	259
Anti-HCV Prevalence †††	**32%**	**42%**	**36%**	**36%**	**40%**	**38%**	**40%**	**35%**	**40%**	**51%**	**47%**
Proportion of samples anti-HCV positive	30%	38%	33%	33%	37%	38%	40%	35%	40%	51%	47%
Number of samples anti-HCV positive	124	172	126	75	96	111	128	135	118	136	123
Total number of samples collected	417	448	385	227	260	294	322	383	298	267	259
Hepatitis B vaccine uptake	**57%**	**63%**	**60%**	**71%**	**64%**	**79%**	**72%**	**71%**	**65%**	**70%**	**75%**
Number reporting hepatitis B vaccine uptake	232	277	227	159	167	224	228	258	188	179	187
Total number answering question	407	442	378	223	259	285	315	365	288	255	250
HCV VCT uptake	**71%**	**76%**	**73%**	**72%**	**80%**	**84%**	**81%**	**82%**	**83%**	**86%**	**86%**
Number reporting a VCT for HCV	278	322	271	160	200	230	239	279	238	222	218
Total number answering question	394	425	372	222	251	274	296	342	288	258	253
Proportion aware of HCV infection	**51%**	**60%**	**51%**	**37%**	**52%**	**57%**	**53%**	**47%**	**43%**	**57%**	**55%**
Number aware of their HCV infection	57	92	57	25	45	54	57	50	41	66	58
Total number answering question	112	154	111	67	87	95	107	106	96	115	106
HIV VCT uptake	**70%**	**71%**	**68%**	**69%**	**74%**	**79%**	**76%**	**82%**	**79%**	**78%**	**83%**
Number reporting a VCT for HIV	278	304	254	152	184	223	234	291	224	201	208
Total number answering question	398	430	376	221	250	282	308	357	282	259	251
Among those who had injected in preceding year											
Symptom§§ of injection site infection		**38%**	**43%**	**38%**	**38%**	**37%**	**26%**	**24%**	**24%**	**29%**	**42%**
Number reporting symptom§§		108	106	57	64	55	57	51	47	56	76
Total number answering question		284	246	149	167	148	219	214	196	190	183
Among those who had injected in preceding four weeks											
Level of direct sharing ‡	**32%**	**26%**	**25%**	**20%**	**20%**	**31%**	**23%**	**20%**	**20%**	**23%**	**22%**
Number reporting direct sharing	82	76	62	30	33	48	39	36	29	38	32
Total number answering question	254	290	253	148	165	154	172	180	148	167	145
Level of sharing (direct & indirect) ‡‡	**53%**	**46%**	**45%**	**38%**	**39%**	**51%**	**47%**	**46%**	**54%**	**55%**	**51%**
Number reporting sharing	134	131	117	56	65	78	80	83	82	93	75
Total number answering question	253	287	261	149	168	154	170	182	153	168	148
Proportion injecting crack		**26%**	**26%**	**36%**	**31%**	**25%**	**34%**	**38%**	**35%**	**64%**	**66%**
Number reporting crack injection		74	69	55	51	39	58	68	54	107	101
Total number answering question		289	265	151	167	156	169	180	156	167	152
Proportion injecting into their groin		**41%**	**35%**	**37%**	**34%**	**37%**	**34%**	**33%**	**39%**	**36%**	**42%**
Number reporting groin injection		110	89	54	56	56	58	60	61	60	64
Total number answering question		269	256	147	165	153	171	184	155	165	152
Among those with two or more (anal or vaginal) sexual partners in preceding year											
Proportion always using a condom	**25%**	**23%**	**14%**	**20%**	**10%**	**20%**	**17%**	**11%**	**18%**	**16%**	**21%**
Number always using a condom	31	32	17	13	7	19	18	14	13	12	13
Total number answering question	125	138	118	64	68	95	109	130	73	75	62

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

‡ Sharing of needles and syringes in preceding four weeks.

‡‡ Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 19: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region West Midlands: 2005-2015

Notes: Behavioural data have not been collected in all years. In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2005	2006	2007	2008	2009		2010		2011	2012	2013	2014	2015
Sample type	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*DBS*	*Oral fluid**	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*
Anti-HIV Prevalence †	**1.4%**		**0.43%**	**0.43%**	**0%**		**0%**		**1.4%**	**1.8%**	**1.5%**	**0%**	**0%**
Number of samples anti-HIV positive	2		1	1	0		0		4	4	6	0	0
Total number of samples collected	145		235	231	315		291		276	228	412	291	154
Anti-HBc Prevalence ††	**7.4%**		**6.2%**	**5.2%**	**7.7%**		**6.3%**		**8.3%**	**7.0%**	**10%**	**5.2%**	**3.2%**
Proportion of samples anti-HBc positive	5.5%		4.7%	3.9%	7.7%	2.8%	7.7%	5.4%	8.3%	7.0%	10%	5.2%	3.2%
Number of samples anti-HBc positive	8		11	9	16	3	4	13	23	16	43	15	5
Total number of samples collected	145		235	231	207	108	52	239	276	228	412	291	154
Anti-HCV Prevalence †††	**23%**		**30%**	**29%**	**36%**		**28%**		**33%**	**37%**	**42%**	**36%**	**26%**
Proportion of samples anti-HCV positive	21%		28%	26%	34%	33%	42%	24%	33%	37%	42%	36%	26%
Number of samples anti-HCV positive	31		65	61	70	36	22	57	90	84	174	104	40
Total number of samples collected	145		235	231	207	108	52	239	276	228	412	291	154
Hepatitis B vaccine uptake	**53%**		**61%**	**59%**	**67%**		**65%**		**76%**	**71%**	**64%**	**69%**	**71%**
Number reporting hepatitis B vaccine uptake	76		142	130	209		187		204	160	257	195	108
Total number answering question	144		234	222	312		287		270	224	401	282	153
HCV VCT uptake	**57%**		**70%**	**64%**	**71%**		**64%**		**73%**	**76%**	**77%**	**80%**	**86%**
Number reporting a VCT for HCV	79		154	138	217		181		190	156	314	224	129
Total number answering question	139		221	215	306		284		259	204	406	281	150
Proportion aware of HCV infection	**23%**		**45%**	**38%**	**46%**		**44%**		**29%**	**53%**	**46%**	**55%**	**53%**
Number aware of their HCV infection	7		27	21	45		32		22	38	68	45	18
Total number answering question	30		60	56	97		73		77	72	149	82	34
HIV VCT uptake	**55%**		**64%**	**66%**	**68%**		**61%**		**72%**	**75%**	**70%**	**74%**	**78%**
Number reporting a VCT for HIV	78		145	147	211		172		191	164	276	207	116
Total number answering question	141		225	224	309		284		265	220	393	279	149
Among those who had injected in preceding year													
Symptom§§ of injection site infection			**34%**	**34%**	**34%**		**26%**		**24%**	**23%**	**29%**	**26%**	**26%**
Number reporting symptom§§			57	49	57		31		33	30	73	49	25
Total number answering question			167	145	166		119		136	131	256	185	97
Among those who had injected in preceding four weeks													
Level of direct sharing ‡	**21%**		**18%**	**13%**	**16%**		**12%**		**13%**	**11%**	**15%**	**15%**	**4.0%**
Number reporting direct sharing	24		31	21	32		16		13	12	36	23	3
Total number answering question	114		168	157	194		131		97	106	233	151	75
Level of sharing (direct & indirect) ‡‡	**43%**		**39%**	**30%**	**31%**		**25%**		**32%**	**28%**	**32%**	**37%**	**25%**
Number reporting sharing	49		68	47	60		33		31	29	74	57	19
Total number answering question	115		173	157	194		131		97	105	234	153	75
Proportion injecting crack			**43%**	**35%**	**33%**		**24%**		**34%**	**54%**	**45%**	**35%**	**33%**
Number reporting crack injection			75	57	64		31		32	58	107	54	25
Total number answering question			174	163	193		130		95	107	237	155	76
Proportion injecting into their groin			**41%**	**34%**	**40%**		**35%**		**32%**	**35%**	**38%**	**31%**	**32%**
Number reporting groin injection			70	56	77		46		30	38	92	48	24
Total number answering question			172	164	192		130		95	110	244	157	76
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	**15%**		**22%**	**17%**	**24%**		**22%**		**23%**	**14%**	**21%**	**27%**	**27%**
Number always using a condom	7		17	11	21		17		16	9	19	16	8
Total number answering question	48		76	64	89		78		71	65	92	60	30

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

‡ Sharing of needles and syringes in preceding four weeks.

‡‡ Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 20: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region North West: 2005-2015

Notes: Behavioural data have not been collected in all years. In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2005	2006	2007	2008	2009		2010		2011	2012	2013	2014	2015
Sample type	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*DBS*	*Oral fluid**	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*
Anti-HIV Prevalence †	**1.4%**	**1.1%**	**0.82%**	**2.6%**	**2.3%**		**1.8%**		**1.8%**	**2.2%**	**0%**	**0%**	**0.48%**
Number of samples anti-HIV positive	7	6	4	11	10		8		7	9	0	0	2
Total number of samples collected	489	553	489	427	428		434		397	409	379	383	414
Anti-HBc Prevalence ††	**42%**	**43%**	**34%**	**29%**	**25%**		**27%**		**28%**	**29%**	**32%**	**27%**	**23%**
Proportion of samples anti-HBc positive	31%	32%	26%	22%	18%	26%	24%	26%	28%	29%	32%	27%	23%
Number of samples anti-HBc positive	153	178	126	94	72	9	20	91	110	117	122	102	94
Total number of samples collected	489	553	489	426	393	35	84	350	397	409	379	383	414
Anti-HCV Prevalence †††	**64%**	**67%**	**64%**	**63%**	**62%**		**65%**		**60%**	**64%**	**68%**	**66%**	**68%**
Proportion of samples anti-HCV positive	59%	61%	59%	58%	56%	63%	68%	63%	60%	64%	68%	66%	68%
Number of samples anti-HCV positive	288	340	288	246	222	22	57	219	239	263	258	251	281
Total number of samples collected	489	553	489	427	393	35	84	350	397	409	379	383	414
Hepatitis B vaccine uptake	**55%**	**68%**	**68%**	**75%**	**74%**		**75%**		**81%**	**77%**	**71%**	**70%**	**81%**
Number reporting hepatitis B vaccine uptake	266	371	323	311	313		320		316	310	258	256	327
Total number answering question	484	545	477	417	423		429		389	401	362	367	402
HCV VCT uptake	**69%**	**75%**	**76%**	**81%**	**82%**		**86%**		**88%**	**85%**	**78%**	**81%**	**90%**
Number reporting a VCT for HCV	322	393	347	333	342		355		311	303	283	297	359
Total number answering question	466	523	456	410	415		413		352	356	363	366	400
Proportion aware of HCV infection	**47%**	**42%**	**41%**	**49%**	**52%**		**54%**		**56%**	**56%**	**44%**	**57%**	**52%**
Number aware of their HCV infection	123	127	103	103	114		140		111	110	98	123	129
Total number answering question	264	299	251	210	218		258		199	197	223	215	250
HIV VCT uptake	**64%**	**62%**	**66%**	**73%**	**72%**		**79%**		**81%**	**79%**	**65%**	**69%**	**80%**
Number reporting a VCT for HIV	294	333	306	301	295		332		306	306	233	250	317
Total number answering question	462	537	466	412	412		420		379	388	356	361	395
Among those who had injected in preceding year													
Symptom§§ of injection site infection		**35%**	**40%**	**37%**	**37%**		**32%**		**25%**	**31%**	**23%**	**28%**	**32%**
Number reporting symptom§§		106	114	88	88		59		50	58	39	54	65
Total number answering question		303	287	236	236		185		199	187	171	191	205
Among those who had injected in preceding four weeks													
Level of direct sharing ‡	**24%**	**23%**	**21%**	**16%**	**13%**		**15%**		**11%**	**12%**	**14%**	**14%**	**15%**
Number reporting direct sharing	69	76	60	36	30		26		18	20	21	22	27
Total number answering question	289	330	285	226	228		179		162	161	145	156	181
Level of sharing (direct & indirect) ‡‡	**45%**	**49%**	**44%**	**39%**	**28%**		**29%**		**29%**	**30%**	**34%**	**38%**	**34%**
Number reporting sharing	131	161	129	89	65		52		47	49	50	60	61
Total number answering question	289	331	292	227	229		179		160	161	146	157	180
Proportion injecting crack		**55%**	**53%**	**56%**	**36%**		**28%**		**31%**	**32%**	**48%**	**50%**	**54%**
Number reporting crack injection		183	152	127	80		51		49	53	72	80	98
Total number answering question		330	287	226	224		179		160	165	150	159	183
Proportion injecting into their groin		**47%**	**38%**	**41%**	**46%**		**40%**		**44%**	**38%**	**45%**	**42%**	**46%**
Number reporting groin injection		138	106	93	105		71		71	64	67	67	84
Total number answering question		292	279	226	226		179		162	168	150	159	181
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	**23%**	**19%**	**27%**	**21%**	**21%**		**26%**		**26%**	**27%**	**15%**	**28%**	**26%**
Number always using a condom	29	23	34	20	22		26		25	24	11	17	18
Total number answering question	124	119	124	94	106		99		98	90	74	60	69

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

‡ Sharing of needles and syringes in preceding four weeks.

‡‡ Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 21: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region Yorkshire & Humber: 2005-2015

Notes: Behavioural data have not been collected in all years. In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2005	2006	2007	2008	2009	2010		2011	2012	2013	2014	2015
Sample type	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*
Anti-HIV Prevalence †	**0%**	**0%**	**0%**	**0%**		**0%**		**0%**	**0%**	**0.29%**	**0.25%**	**0%**
Number of samples anti-HIV positive	0	0	0	0		0		0	0	1	1	0
Total number of samples collected	133	148	113	261		402		297	299	341	396	228
Anti-HBc Prevalence ††	**4.0%**	**7.2%**	**9.4%**	**6.6%**		**16%**		**11%**	**8.7%**	**12%**	**8.8%**	**4.4%**
Proportion of samples anti-HBc positive	3.0%	5.4%	7.1%	5.0%		4.6%	18%	11%	8.7%	12%	8.8%	4.4%
Number of samples anti-HBc positive	4	8	8	13		4	58	34	26	42	35	10
Total number of samples collected	133	148	113	261		87	315	297	299	341	396	228
Anti-HCV Prevalence †††	**38%**	**32%**	**38%**	**42%**		**52%**		**47%**	**57%**	**50%**	**52%**	**48%**
Proportion of samples anti-HCV positive	35%	29%	35%	39%		51%	52%	47%	57%	50%	52%	48%
Number of samples anti-HCV positive	47	43	39	102		44	163	140	171	172	207	110
Total number of samples collected	133	148	113	261		87	315	297	299	341	396	228
Hepatitis B vaccine uptake	**78%**	**76%**	**79%**	**80%**		**76%**		**78%**	**83%**	**77%**	**78%**	**78%**
Number reporting hepatitis B vaccine uptake	101	110	81	207		300		215	237	257	292	164
Total number answering question	129	145	102	258		394		276	286	332	374	211
HCV VCT uptake	**69%**	**68%**	**74%**	**76%**		**85%**		**81%**	**84%**	**82%**	**82%**	**81%**
Number reporting a VCT for HCV	87	92	67	184		320		205	238	265	307	173
Total number answering question	126	135	91	243		375		252	285	322	376	213
Proportion aware of HCV infection	**32%**	**32%**	**56%**	**56%**		**51%**		**46%**	**57%**	**49%**	**49%**	**63%**
Number aware of their HCV infection	12	12	14	45		89		51	88	71	85	60
Total number answering question	38	38	25	80		173		111	154	146	173	96
HIV VCT uptake	**54%**	**66%**	**57%**	**59%**		**68%**		**72%**	**75%**	**72%**	**72%**	**74%**
Number reporting a VCT for HIV	68	89	52	143		257		188	207	234	263	158
Total number answering question	127	135	91	243		378		262	276	326	366	214
Among those who had injected in preceding year												
Symptom§§ of injection site infection		**31%**	**46%**	**28%**		**35%**		**37%**	**29%**	**26%**	**34%**	**34%**
Number reporting symptom§§		19	17	29		61		48	56	52	72	48
Total number answering question		61	37	102		174		131	193	202	211	141
Among those who had injected in preceding four weeks												
Level of direct sharing ‡	**47%**	**13%**	**38%**	**18%**		**23%**		**12%**	**17%**	**14%**	**13%**	**15%**
Number reporting direct sharing	20	7	11	16		54		13	27	25	23	17
Total number answering question	43	54	29	88		230		107	157	179	183	115
Level of sharing (direct & indirect) ‡‡	**71%**	**30%**	**60%**	**34%**		**45%**		**38%**	**40%**	**41%**	**36%**	**44%**
Number reporting sharing	30	16	18	30		102		41	63	73	67	51
Total number answering question	42	54	30	88		225		107	157	179	188	117
Proportion injecting crack		**60%**	**60%**	**51%**		**33%**		**44%**	**41%**	**43%**	**35%**	**56%**
Number reporting crack injection		32	18	45		75		47	65	78	67	67
Total number answering question		53	30	89		225		107	160	183	189	119
Proportion injecting into their groin		**31%**	**23%**	**36%**		**42%**		**45%**	**45%**	**49%**	**41%**	**48%**
Number reporting groin injection		16	7	32		96		48	71	92	78	57
Total number answering question		51	30	89		226		107	159	187	190	119
Among those with two or more (anal or vaginal) sexual partners in preceding year												
Proportion always using a condom	**19%**	**13%**	**13%**	**12%**		**21%**		**15%**	**15%**	**16%**	**17%**	**26%**
Number always using a condom	7	5	3	8		21		13	12	13	11	12
Total number answering question	37	40	23	67		100		85	82	80	66	47

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

‡ Sharing of needles and syringes in preceding four weeks.

‡‡ Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 22: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region East Midlands: 2005-2015

Notes: Behavioural data have not been collected in all years. In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2005	2006	2007	2008	2009		2010	2011	2012	2013	2014	2015
Sample type	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*
Anti-HIV Prevalence †	**0.50%**	**0%**	**0.32%**	**0.86%**	**1.4%**		**0.87%**	**0.97%**	**1.1%**	**0.93%**	**2.5%**	**2.2%**
Number of samples anti-HIV positive	1	0	1	3	4		2	2	3	3	8	5
Total number of samples collected	202	182	310	349	289		229	206	281	322	319	231
Anti-HBc Prevalence ††	**17%**	**13%**	**8.6%**	**8.0%**	**4.6%**		**14%**	**8.7%**	**12%**	**11%**	**12%**	**14%**
Proportion of samples anti-HBc positive	13%	10%	6.5%	6.0%	2.8%	5.5%	14%	8.7%	12%	11%	12%	14%
Number of samples anti-HBc positive	26	18	20	21	4	8	33	18	34	37	37	32
Total number of samples collected	202	182	310	349	144	145	229	206	281	322	319	231
Anti-HCV Prevalence †††	**47%**	**41%**	**29%**	**31%**	**44%**		**46%**	**33%**	**44%**	**49%**	**47%**	**51%**
Proportion of samples anti-HCV positive	44%	37%	27%	29%	33%	52%	46%	33%	44%	49%	47%	51%
Number of samples anti-HCV positive	88	68	84	100	47	76	105	68	125	159	151	117
Total number of samples collected	202	182	310	349	144	145	229	206	281	322	319	231
Hepatitis B vaccine uptake	**68%**	**68%**	**74%**	**78%**	**79%**		**80%**	**81%**	**79%**	**77%**	**75%**	**74%**
Number reporting hepatitis B vaccine uptake	134	122	226	266	226		181	162	216	232	231	163
Total number answering question	197	180	306	342	287		226	200	274	302	306	219
HCV VCT uptake	**74%**	**69%**	**70%**	**79%**	**85%**		**87%**	**83%**	**85%**	**84%**	**86%**	**90%**
Number reporting a VCT for HCV	139	117	206	261	235		186	153	214	251	265	203
Total number answering question	189	169	295	332	276		213	184	251	298	308	225
Proportion aware of HCV infection	**42%**	**28%**	**31%**	**35%**	**38%**		**52%**	**37%**	**46%**	**41%**	**47%**	**59%**
Number aware of their HCV infection	32	16	22	30	43		48	21	47	55	63	62
Total number answering question	77	57	71	85	112		92	57	102	134	135	105
HIV VCT uptake	**66%**	**60%**	**58%**	**69%**	**70%**		**69%**	**68%**	**72%**	**75%**	**74%**	**81%**
Number reporting a VCT for HIV	126	104	174	232	196		146	130	186	225	219	174
Total number answering question	191	174	298	335	279		212	190	260	299	294	216
Among those who had injected in preceding year												
Symptom§§ of injection site infection		**33%**	**37%**	**24%**	**25%**		**29%**	**24%**	**28%**	**25%**	**29%**	**28%**
Number reporting symptom§§		45	77	62	51		42	36	54	60	68	43
Total number answering question		137	208	259	204		144	147	191	236	238	153
Among those who had injected in preceding four weeks												
Level of direct sharing ‡	**25%**	**20%**	**20%**	**19%**	**14%**		**18%**	**15%**	**11%**	**13%**	**14%**	**19%**
Number reporting direct sharing	46	33	43	48	29		29	20	19	30	33	27
Total number answering question	182	162	213	258	207		162	134	173	225	230	143
Level of sharing (direct & indirect) ‡‡	**53%**	**48%**	**41%**	**40%**	**40%**		**33%**	**31%**	**34%**	**35%**	**32%**	**31%**
Number reporting sharing	97	79	90	88	83		53	42	58	79	73	44
Total number answering question	182	163	218	221	207		162	134	173	227	231	144
Proportion injecting crack		**33%**	**30%**	**23%**	**18%**		**36%**	**27%**	**34%**	**28%**	**37%**	**49%**
Number reporting crack injection		54	67	62	38		59	37	61	64	85	73
Total number answering question		163	223	268	206		166	136	177	228	230	148
Proportion injecting into their groin		**41%**	**36%**	**36%**	**40%**		**37%**	**31%**	**43%**	**39%**	**44%**	**29%**
Number reporting groin injection		67	78	95	81		60	43	77	89	104	42
Total number answering question		164	218	261	201		164	138	178	229	235	147
Among those with two or more (anal or vaginal) sexual partners in preceding year												
Proportion always using a condom	**11%**	**22%**	**10%**	**15%**	**10%**		**7.9%**	**8.9%**	**8.8%**	**18%**	**23%**	**22%**
Number always using a condom	8	14	8	16	7		5	5	7	13	19	11
Total number answering question	75	63	83	109	70		63	56	80	73	81	49

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

‡ Sharing of needles and syringes in preceding four weeks.

‡‡ Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 23: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region North East: 2005-2015

Notes: Behavioural data have not been collected in all years. In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2005	2006	2007	2008	2009		2010		2011	2012	2013	2014	2015
Sample type	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*DBS*	*Oral fluid**	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*
Anti-HIV Prevalence †	**0%**	**0%**	**0.33%**	**0.40%**	**0.91%**		**0.35%**		**0%**	**0.27%**	**0.38%**	**0%**	**0%**
Number of samples anti-HIV positive	0	0	1	1	3		1		0	1	1	0	0
Total number of samples collected	293	273	301	252	331		284		217	364	260	225	157
Anti-HBc Prevalence ††	**13%**	**17%**	**12%**	**11%**	**10%**		**11%**		**11%**	**11%**	**10%**	**8.0%**	**5.7%**
Proportion of samples anti-HBc positive	10%	12%	8.6%	7.9%	9.0%	6.1%	9.4%	3.3%	11%	11%	10%	8.0%	5.7%
Number of samples anti-HBc positive	29	34	26	20	18	8	21	2	24	39	26	18	9
Total number of samples collected	293	273	301	252	200	131	223	61	217	364	260	225	157
Anti-HCV Prevalence †††	**23%**	**24%**	**21%**	**25%**	**33%**		**29%**		**33%**	**33%**	**37%**	**29%**	**36%**
Proportion of samples anti-HCV positive	21%	22%	19%	23%	26%	40%	22%	44%	33%	33%	37%	29%	36%
Number of samples anti-HCV positive	62	60	58	59	52	53	50	27	71	121	95	66	57
Total number of samples collected	293	273	301	252	200	131	223	61	217	364	260	225	157
Hepatitis B vaccine uptake	**74%**	**77%**	**80%**	**83%**	**87%**		**88%**		**79%**	**75%**	**74%**	**70%**	**79%**
Number reporting hepatitis B vaccine uptake	206	206	237	203	282		241		162	268	184	153	118
Total number answering question	278	269	296	246	324		274		204	355	248	219	149
HCV VCT uptake	**62%**	**71%**	**70%**	**74%**	**77%**		**87%**		**82%**	**80%**	**81%**	**71%**	**83%**
Number reporting a VCT for HCV	166	187	204	172	236		227		151	256	197	153	124
Total number answering question	269	262	293	233	305		261		184	319	244	216	149
Proportion aware of HCV infection	**22%**	**29%**	**26%**	**43%**	**34%**		**44%**		**33%**	**36%**	**36%**	**29%**	**33%**
Number aware of their HCV infection	11	15	14	23	32		27		20	35	32	16	16
Total number answering question	50	52	53	54	93		62		60	97	88	55	49
HIV VCT uptake	**54%**	**63%**	**67%**	**68%**	**71%**		**80%**		**76%**	**74%**	**75%**	**67%**	**73%**
Number reporting a VCT for HIV	146	172	197	161	226		214		143	250	185	143	110
Total number answering question	270	271	292	238	317		269		187	340	246	212	150
Among those who had injected in preceding year													
Symptom§§ of injection site infection		**27%**	**29%**	**24%**	**35%**		**38%**		**27%**	**27%**	**31%**	**29%**	**23%**
Number reporting symptom§§		54	58	40	74		62		37	66	52	44	25
Total number answering question		203	203	167	212		165		139	243	168	151	111
Among those who had injected in preceding four weeks													
Level of direct sharing ‡	**32%**	**24%**	**25%**	**19%**	**21%**		**21%**		**19%**	**16%**	**22%**	**22%**	**16%**
Number reporting direct sharing	72	55	63	36	48		43		23	34	35	30	16
Total number answering question	223	225	252	189	232		207		119	210	158	137	97
Level of sharing (direct & indirect) ‡‡	**51%**	**40%**	**38%**	**31%**	**32%**		**33%**		**38%**	**36%**	**42%**	**43%**	**30%**
Number reporting sharing	114	90	95	57	76		69		45	75	67	59	29
Total number answering question	222	226	252	186	234		209		119	211	159	137	97
Proportion injecting crack		**7.5%**	**14%**	**4.5%**	**5.1%**		**9.6%**		**2.5%**	**6.5%**	**11%**	**5.8%**	**8.2%**
Number reporting crack injection		17	37	9	12		20		3	14	18	8	8
Total number answering question		228	257	198	234		208		120	215	165	139	97
Proportion injecting into their groin		**32%**	**28%**	**31%**	**27%**		**25%**		**33%**	**34%**	**41%**	**38%**	**39%**
Number reporting groin injection		71	71	60	61		51		40	72	68	54	39
Total number answering question		221	255	196	226		202		122	213	165	141	99
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	**10%**	**15%**	**11%**	**15%**	**10%**		**23%**		**6.5%**	**13%**	**15%**	**7.1%**	**13%**
Number always using a condom	12	15	11	14	12		19		5	17	10	4	5
Total number answering question	123	99	100	93	116		84		77	132	68	56	39

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

‡ Sharing of needles and syringes in preceding four weeks.

‡‡ Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 24: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; Wales: 2003/5-2015

Notes: Behavioural data have not been collected in all years. In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different. There were changes in the participating areas in Wales during 2013.

Year	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
Sample type	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*
Anti-HIV Prevalence †		**1.4%**		**0%**	**0.30%**	**1.8%**	**0.57%**	**0%**	**1.1%**	**0%**	**0.50%**	**1.1%**	**0.77%**
Number of samples anti-HIV positive		4		0	1	3	1	0	2	0	1	3	2
Total number of samples collected		286		182	330	164	174	196	175	236	201	270	261
Anti-HBc Prevalence ††		**9.3%**		**23%**	**12%**	**12%**	**4.6%**	**5.4%**	**11%**	**10%**	**13%**	**11%**	**11%**
Proportion of samples anti-HBc positive		7.0%		18%	9.1%	9.1%	3.4%	4.1%	11%	10%	13%	11%	11%
Number of samples anti-HBc positive		20		32	30	15	6	8	20	23	26	30	28
Total number of samples collected		286		182	330	164	174	196	175	236	201	270	261
Anti-HCV Prevalence †††		**19%**		**20%**	**24%**	**31%**	**32%**	**26%**	**39%**	**33%**	**47%**	**50%**	**53%**
Proportion of samples anti-HCV positive		17%		19%	22%	29%	29%	24%	39%	33%	47%	50%	53%
Number of samples anti-HCV positive		49		34	73	47	51	47	68	77	94	136	138
Total number of samples collected		286		182	330	164	174	196	175	236	201	270	261
Hepatitis B vaccine uptake		**43%**		**52%**	**60%**	**60%**	**72%**	**64%**	**79%**	**77%**	**74%**	**76%**	**74%**
Number reporting hepatitis B vaccine uptake		121		95	192	98	120	125	136	178	144	195	187
Total number answering question		282		181	321	163	167	194	173	231	195	256	253
HCV VCT uptake		**50%**		**60%**	**61%**	**74%**	**75%**	**62%**	**86%**	**84%**	**84%**	**85%**	**81%**
Number reporting a VCT for HCV		136		103	181	116	123	114	138	176	165	223	206
Total number answering question		274		172	299	157	163	185	161	210	196	261	254
Proportion aware of HCV infection		**29%**		**59%**	**30%**	**51%**	**45%**	**34%**	**56%**	**42%**	**38%**	**48%**	**47%**
Number aware of their HCV infection		14		17	18	20	19	12	32	26	33	59	53
Total number answering question		48		29	60	39	42	35	57	62	86	123	112
HIV VCT uptake		**48%**		**57%**	**57%**	**65%**	**72%**	**62%**	**77%**	**80%**	**72%**	**79%**	**75%**
Number reporting a VCT for HIV		132		100	180	100	121	115	124	175	137	202	189
Total number answering question		277		175	314	154	169	185	162	220	190	256	252
Among those who had injected in preceding year													
Symptom§§ of injection site infection				**30%**	**30%**	**32%**	**20%**	**24%**	**30%**	**27%**	**29%**	**35%**	**39%**
Number reporting symptom§§				28	58	24	19	21	34	43	41	67	77
Total number answering question				94	194	75	93	87	112	161	143	193	197
Among those who had injected in preceding four weeks													
Level of direct sharing ‡		**21%**		**23%**	**17%**	**28%**	**17%**	**20%**	**11%**	**10%**	**21%**	**22%**	**13%**
Number reporting direct sharing		33		23	29	19	18	16	12	14	26	34	23
Total number answering question		156		102	173	68	103	81	111	134	125	158	183
Level of sharing (direct & indirect) ‡‡		**54%**		**45%**	**35%**	**50%**	**32%**	**41%**	**30%**	**25%**	**44%**	**41%**	**42%**
Number reporting sharing		83		46	62	34	32	33	33	34	56	66	78
Total number answering question		155		102	175	68	100	81	111	134	126	162	186
Proportion injecting crack				**5.2%**	**20%**	**13%**	**6.8%**	**8.6%**	**19%**	**22%**	**21%**	**18%**	**24%**
Number reporting crack injection				5	36	9	7	7	21	29	26	30	43
Total number answering question				97	181	71	103	81	108	133	124	165	179
Proportion injecting into their groin				**13%**	**25%**	**26%**	**8.8%**	**15%**	**32%**	**33%**	**29%**	**39%**	**40%**
Number reporting groin injection				13	45	18	9	12	36	44	37	64	75
Total number answering question				97	182	70	102	80	111	135	129	165	187
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom		**11%**		**19%**	**11%**	**11%**	**18%**	**27%**	**28%**	**7.0%**	**20%**	**21%**	**20%**
Number always using a condom		10		10	11	4	8	16	12	3	10	14	14
Total number answering question		88		53	98	37	45	59	43	43	50	67	71

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

‡ Sharing of needles and syringes in preceding four weeks.

‡‡ Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 25: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; Northern Ireland: 2005-2015

Notes: Behavioural data have not been collected in all years. In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
Sample type	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*
Anti-HIV Prevalence †	**2.0%**	**1.8%**	**1.8%**	**2.6%**	**1.3%**	**0%**	**0.56%**	**0%**	**0.62%**	**0.65%**	**0.65%**
Number of samples anti-HIV positive	3	3	3	4	2	0	1	0	1	1	1
Total number of samples collected	148	164	165	152	153	193	178	171	161	154	153
Anti-HBc Prevalence ††	**13%**	**8.9%**	**8.1%**	**7.1%**	**8.7%**	**11%**	**10%**	**5.8%**	**6.8%**	**7.1%**	**6.5%**
Proportion of samples anti-HBc positive	9.5%	6.7%	6.1%	5.3%	6.5%	11%	10%	5.8%	6.8%	7.1%	6.5%
Number of samples anti-HBc positive	14	11	10	8	10	21	18	10	11	11	10
Total number of samples collected	148	164	165	151	153	193	178	171	161	154	153
Anti-HCV Prevalence †††	**31%**	**32%**	**31%**	**36%**	**28%**	**31%**	**29%**	**34%**	**32%**	**23%**	**27%**
Proportion of samples anti-HCV positive	28%	29%	28%	33%	26%	31%	29%	34%	32%	23%	27%
Number of samples anti-HCV positive	42	48	47	50	40	60	51	58	51	36	42
Total number of samples collected	148	164	165	152	153	193	178	171	161	154	153
Hepatitis B vaccine uptake	**71%**	**80%**	**77%**	**82%**	**80%**	**73%**	**68%**	**68%**	**75%**	**78%**	**84%**
Number reporting hepatitis B vaccine uptake	103	127	125	122	115	138	114	116	116	116	121
Total number answering question	145	159	162	149	144	189	167	170	154	148	144
HCV VCT uptake	**90%**	**93%**	**90%**	**95%**	**92%**	**90%**	**90%**	**87%**	**91%**	**88%**	**94%**
Number reporting a VCT for HCV	125	142	138	141	131	170	137	131	137	129	137
Total number answering question	139	153	154	148	143	189	153	150	151	146	145
Proportion aware of HCV infection	**68%**	**74%**	**71%**	**66%**	**52%**	**60%**	**61%**	**53%**	**55%**	**68%**	**58%**
Number aware of their HCV infection	26	31	29	29	16	32	25	27	26	23	22
Total number answering question	38	42	41	44	31	53	41	51	47	34	38
HIV VCT uptake	**73%**	**80%**	**80%**	**84%**	**92%**	**89%**	**89%**	**86%**	**90%**	**91%**	**92%**
Number reporting a VCT for HIV	104	123	124	124	133	167	143	135	136	134	133
Total number answering question	142	154	155	147	145	188	160	157	151	147	144
Among those who had injected in preceding year											
Symptom§§ of injection site infection		**25%**	**32%**	**33%**	**36%**	**32%**	**40%**	**32%**	**33%**	**33%**	**37%**
Number reporting symptom§§		17	21	26	24	18	29	23	22	19	24
Total number answering question		69	65	79	67	56	72	71	67	58	65
Among those who had injected in preceding four weeks											
Level of direct sharing ‡	**21%**	**21%**	**21%**	**17%**	**14%**	**23%**	**29%**	**19%**	**31%**	**17%**	**17%**
Number reporting direct sharing	10	9	9	8	6	10	10	6	11	5	6
Total number answering question	48	42	42	47	43	44	35	32	35	30	36
Level of sharing (direct & indirect) ‡‡	**35%**	**31%**	**33%**	**36%**	**36%**	**36%**	**34%**	**35%**	**42%**	**30%**	**31%**
Number reporting sharing	17	13	14	17	15	16	12	11	15	9	11
Total number answering question	48	42	42	47	42	44	35	31	36	30	36
Proportion injecting crack		**2.3%**	**10%**	**2.2%**	**0%**	**6.8%**	**0%**	**3.3%**	**2.7%**	**3.6%**	**0%**
Number reporting crack injection		1	4	1	0	3	0	1	1	1	0
Total number answering question		43	41	46	40	44	34	30	37	28	36
Proportion injecting into their groin		**32%**	**32%**	**26%**	**30%**	**21%**	**24%**	**41%**	**26%**	**23%**	**46%**
Number reporting groin injection		13	12	12	12	9	8	13	10	7	17
Total number answering question		41	38	47	40	42	34	32	38	31	37
Among those with two or more (anal or vaginal) sexual partners in preceding year											
Proportion always using a condom	**26%**	**24%**	**19%**	**28%**	**19%**	**35%**	**39%**	**11%**	**23%**	**28%**	**33%**
Number always using a condom	9	13	8	10	6	17	14	4	7	7	8
Total number answering question	35	55	42	36	31	49	36	38	31	25	24

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

‡ Sharing of needles and syringes in preceding four weeks.

‡‡ Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 26: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use in those who began injecting in the last three years: 2005-2015

Notes: Behavioural data have not been collected in all years. In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2005	2006	2007	2008	2009		2010		2011	2012	2013	2014	2015
Sample type	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*Oral fluid**	*DBS*	*Oral fluid**	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*	*DBS*
Anti-HIV Prevalence †	**1.3%**	**0.77%**	**1.0%**	**1.3%**	**0.71%**		**0.50%**		**0.37%**	**1.0%**	**1.0%**	**0.41%**	**2.6%**
Number of samples anti-HIV positive	5	3	5	5	3		2		1	4	3	1	6
Total number of samples collected	397	388	484	391	421		403		269	382	304	243	229
Anti-HBc Prevalence ††	**9.4%**	**14%**	**6.3%**	**3.1%**	**7.1%**		**7.4%**		**5.9%**	**7.1%**	**5.9%**	**2.1%**	**3.5%**
Proportion of samples anti-HBc positive	7.1%	10%	4.8%	2.3%	6.1%	2.6%	7.7%	5.7%	5.9%	7.1%	5.9%	2.1%	3%
Number of samples anti-HBc positive	28	40	23	9	21	2	12	14	16	27	18	5	8
Total number of samples collected	397	388	484	391	345	76	156	247	269	382	304	243	229
Anti-HCV Prevalence †††	**18%**	**23%**	**23%**	**24%**	**24%**		**23%**		**20%**	**24%**	**24%**	**19%**	**24%**
Proportion of samples anti-HCV positive	16%	21%	21%	22%	22%	24%	20%	23%	20%	24%	24%	19%	24%
Number of samples anti-HCV positive	64	81	103	87	77	18	31	57	53	90	74	47	55
Total number of samples collected	397	388	484	391	345	76	156	247	269	382	304	243	229
Hepatitis B vaccine uptake	**46%**	**61%**	**54%**	**62%**	**68%**		**64%**		**67%**	**65%**	**62%**	**62%**	**65%**
Number reporting hepatitis B vaccine uptake	179	235	256	238	284		257		178	244	181	144	146
Total number answering question	388	383	477	383	420		400		266	377	294	231	223
HCV VCT Uptake	**49%**	**54%**	**56%**	**61%**	**68%**		**66%**		**72%**	**68%**	**67%**	**70%**	**72%**
Number reporting a VCT for HCV	185	198	257	229	272		253		175	236	198	165	160
Total number answering question	374	367	457	373	402		385		243	346	296	236	221
Proportion aware of HCV infection	**19%**	**35%**	**36%**	**30%**	**31%**		**38%**		**46%**	**41%**	**20%**	**38%**	**39%**
Number aware of their HCV infection	10	25	35	22	26		28		21	31	13	15	17
Total number answering question	54	71	98	73	84		73		46	76	65	39	44
HIV VCT uptake	**51%**	**51%**	**55%**	**59%**	**64%**		**61%**		**63%**	**67%**	**65%**	**67%**	**68%**
Number reporting a VCT for HIV	193	193	257	222	259		235		162	245	192	155	151
Total number answering question	381	377	469	379	405		387		256	364	296	233	222
Among those who had injected in preceding year													
Symptom§§ of injection site infection		**29%**	**29%**	**26%**	**30%**		**32%**		**29%**	**27%**	**24%**	**25%**	**30%**
Number reporting symptom§§		71	89	67	74		66		51	78	53	45	54
Total number answering question		244	303	256	250		205		176	286	221	180	182
Among those who had injected in preceding four weeks													
Level of direct sharing ‡	**28%**	**21%**	**25%**	**17%**	**17%**		**21%**		**19%**	**19%**	**21%**	**20%**	**21%**
Number reporting direct sharing	70	57	86	45	46		51		26	46	39	29	27
Total number answering question	251	268	344	258	263		240		139	243	184	145	127
Level of sharing (direct & indirect) ‡‡	**48%**	**42%**	**41%**	**41%**	**34%**		**39%**		**38%**	**43%**	**46%**	**49%**	**45%**
Number reporting sharing	120	113	144	103	90		93		53	104	85	72	57
Total number answering question	250	267	347	249	265		241		139	240	185	147	128
Proportion injecting crack		**28%**	**26%**	**26%**	**23%**		**22%**		**29%**	**30%**	**31%**	**28%**	**40%**
Number reporting crack injection		73	88	68	60		52		40	73	56	43	53
Total number answering question		265	344	259	261		241		139	241	183	152	131
Proportion injecting into their groin		**15%**	**16%**	**13%**	**19%**		**12%**		**14%**	**13%**	**17%**	**13%**	**15%**
Number reporting groin injection		39	53	33	50		30		19	31	33	20	20
Total number answering question		256	337	249	259		248		140	244	190	151	132
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	**20%**	**20%**	**18%**	**21%**	**17%**		**23%**		**21%**	**15%**	**18%**	**24%**	**15%**
Number always using a condom	25	23	26	24	23		34		19	17	15	15	9
Total number answering question	122	116	141	116	135		146		91	116	84	63	59

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

‡ Sharing of needles and syringes in preceding four weeks.

‡‡ Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 27: Characteristics of the people who inject drugs recruited across England, Wales and Northern Ireland: 2005-2015

Notes:
Data on characteristics have not been collected in all years.

Year	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
Under 25 years old ˜	**15%**	**14%**	**15%**	**13%**	**13%**	**11%**	**8.8%**	**8.8%**	**6.0%**	**5.8%**	**4.3%**
Number aged <25 years	475	455	509	409	400	341	239	287	185	175	116
Total number answering question	3,096	3,145	3,449	3,066	3,120	3,153	2,731	3,254	3,093	3,037	2,678
Female gender˜	**27%**	**27%**	**26%**	**26%**	**26%**	**25%**	**25%**	**26%**	**26%**	**27%**	**27%**
Number female	835	870	908	826	851	790	683	851	817	826	718
Total number answering question	3,137	3,202	3,511	3,170	3,229	3,223	2,785	3,336	3,108	3,067	2,696
Treatment for drug use♦	**66%**	**66%**	**67%**	**70%**	**73%**	**73%**	**74%**	**67%**	**69%**	**69%**	**70%**
Number reporting current treatment	2,068	2,134	2,355	2,226	2,352	2,360	2,060	2,231	2,137	2,120	1,881
Total number answering question	3,136	3,210	3,522	3,178	3,238	3,230	2,791	3,337	3,119	3,061	2,690
Ever used a needle exchange	**90%**	**91%**	**92%**	**91%**	**92%**	**91%**	**92%**	**91%**	**91%**	**89%**	**90%**
Number reporting use of needle exchange	2,806	2,894	3,211	2,880	2,947	2,934	2,530	2,980	2,818	2,709	2,404
Total number answering question	3,118	3,194	3,508	3,159	3,220	3,224	2,760	3,290	3,097	3,034	2,667
Ever been in prison	**64%**	**66%**	**68%**	**68%**	**72%**	**70%**	**71%**	**72%**	**71%**	**69%**	**67%**
Number reporting ever being imprisoned	1,957	2,052	2,326	2,106	2,266	2,186	1,922	2,319	2,194	2,084	1,793
Total number answering question	3,042	3,132	3,435	3,089	3,144	3,132	2,704	3,241	3,072	3,022	2,659
Ever been homeless		**74%**	**76%**	**74%**	**77%**	**76%**	**77%**	**78%**	**76%**	**74%**	**74%**
Number reporting ever being homeless		2,200	2,574	2,278	2,409	2,381	2,075	2,529	2,332	2,228	1,967
Total number answering question		2,979	3,405	3,064	3,137	3,132	2,710	3,255	3,075	3,016	2,652
Ever traded sex for money, goods or drugs							**14%**	**13%**	**12%**	**12%**	**13%**
Number reporting ever trading sex♦♦							334	384	345	358	335
Total number answering question							2,412	2,997	3,000	2,924	2,586
Among those who had injected in preceding four weeks											
Stimulant drugs											
Proportion injecting crack		**35%**	**35%**	**35%**	**29%**	**29%**	**32%**	**36%**	**37%**	**40%**	**46%**
Number reporting crack injection		657	748	640	526	499	421	596	615	627	659
Total number answering question		1,887	2,124	1,837	1,808	1,706	1,301	1,672	1,663	1,572	1,428
Proportion injecting cocaine♦♦♦		**12%**	**12%**	**11%**	**7.7%**	**6.6%**	**8.5%**	**8.7%**	**6.9%**	**7.6%**	**9.7%**
Number reporting cocaine injection		218	247	199	140	112	110	145	115	119	139
Total number answering question		1,887	2,124	1,837	1,808	1,706	1,301	1,672	1,663	1,572	1,428
Proportion injecting amphetamine ♦♦♦		**16%**	**19%**	**18%**	**17%**	**18%**	**23%**	**22%**	**23%**	**24%**	**17%**
Number reporting amphetamine injection		303	394	330	314	308	302	364	382	375	247
Total number answering question		1,887	2,124	1,837	1,808	1,706	1,301	1,672	1,663	1,572	1,428
Higher risk injection sites											
Proportion injecting into their groin		**35%**	**32%**	**32%**	**35%**	**34%**	**35%**	**35%**	**38%**	**38%**	**38%**
Number reporting groin injection		623	676	579	618	567	459	584	634	598	548
Total number answering question		1,800	2,099	1,808	1,781	1,687	1,315	1,690	1,682	1,584	1,440
Proportion injecting into their hands♦♦♦		**26%**	**25%**	**25%**	**28%**	**27%**	**27%**	**25%**	**26%**	**30%**	**29%**
Number reporting injecting into their hands		461	526	453	491	453	361	430	435	475	418
Total number answering question		1,800	2,099	1,808	1,781	1,687	1,315	1,690	1,682	1,584	1,440
Proportion injecting into their legs♦♦♦		**19%**	**19%**	**18%**	**19%**	**18%**	**21%**	**20%**	**21%**	**23%**	**26%**
Number reporting injecting into their legs		338	401	321	331	311	279	342	356	371	375
Total number answering question		1,800	2,099	1,808	1,781	1,687	1,315	1,690	1,682	1,584	1,440
Proportion injecting into their feet♦♦♦		**11%**	**13%**	**10%**	**12%**	**11%**	**11%**	**11%**	**11%**	**11%**	**13%**
Number reporting injecting into their feet		206	264	189	211	190	149	190	178	181	191
Total number answering question		1,800	2,099	1,808	1,781	1,687	1,315	1,690	1,682	1,584	1,440

˜ Age and gender not provided by all participants.
♦Prescribed a detox or maintenance drug regime.
♦♦Self-reports of ever receiving money, goods or drugs in exchange for sex.
♦♦♦ Regional breakdowns not provided due to small numbers.